

OFFICE OF ENTERPRISE TECHNOLOGY SERVICES

P.O. BOX 119, HONOLULU, HAWAI'I 96810-0119 Ph: (808) 586-6000 | Fax: (808) 586-1922 FTS HAWAII GOV

March 23, 2021

The Honorable Ronald D. Kouchi,
President, and
Members of The Senate
Thirty-First State Legislature
Hawaii State Capitol, Room 409
Honolulu, Hawaii 96813

The Honorable Scott K. Saiki, Speaker, and Members of The House of Representatives Thirty-First State Legislature Hawaii State Capitol, Room 431 Honolulu, Hawaii 96813

Dear President Kouchi, Speaker Saiki, and Members of the Legislature:

Pursuant to HRS section 27-43.6, which requires the Chief Information Officer to submit applicable independent verification and validation (IV&V) reports to the Legislature within ten days of receiving the report, please find attached the report the Office of Enterprise Technology Services received for the State of Hawaii Department of Health Hawaii BHA Integrated Case Management System Project.

In accordance with HRS section 93-16, this report may be viewed electronically at http://ets.hawaii.gov (see "Reports").

Sincerely,

DOUGLAS MURDOCK Chief Information Officer State of Hawai'i

Attachment (2)



Hawaii BHA Integrated Case Management System Project – *Phase 3*

Final IV&V Report for the period of

February 1 – February 28, 2021

Final submitted: March 8, 2021



Agenda

Executive Summary IV&V Findings & Recommendations

Appendices

- A Rating Scales
- B Inputs
- C Project Trends





Executive Summary

The Project deployed Release 3.12 (R3.12) to production on 2/14/2021. Post-production issues and deprecated system functionality resulted. Due to the higher volume of post-production defects, BHA is pursuing a Root Cause Analysis (RCA) to address the R3.12 defects, which IV&V recommended and believes should be instituted as part of all future post-production deployment activities to promote continuous quality improvement.

IV&V continues to monitor high criticality findings for release deployment, regression testing, quality, and Microsoft Issues. We encourage the Project to consider our recommendations to mitigate risk and avoid the reoccurrence of issues in upcoming planned releases.

Initial production deployments for both the IDM and Semantics Layer workstreams were completed on 2/26/2021. Efforts to prioritize the planning for additional workstream phases are underway.

Dec	Jan	Feb	Category	IV&V Observations
Y	Y	Y	Sprint Planning	Although IV&V continues to recommend the need for skilled MS Dynamics resources to permanently support BHA's technical needs, CAMHD's recruitment activities continue to be delayed due to lack of administrative approvals to post the open IT Technician position. The rating for this category remains Yellow (medium criticality) for the February reporting period. IV&V will continue to monitor this category moving forward.
G	G User Story (US) Validation There are no active findings in User Story (US) Validation category which remains Gr (low criticality) for the February reporting period. IV&V will continue to monitor the US development and validation process in upcoming reporting periods.			
Y	R	R	Test Practice Validation The project deployed R3.12 to production in February which again resulted in post release defects and deprecated system functionality. The project is performing an RCA determine the source of defects as it pertains to testing. IV&V continues to recommend the development of automated regression test scripts. The rating for this category remarked (high) for the February reporting period. IV&V will continue to monitor this category upcoming reporting periods.	




Executive Summary

Dec	Jan	Feb	Category	IV&V Observations	
Y	R	R	Release / Deployment Planning	The criticality rating for this category remains Red (high) for the February reporting period. Deployment issues continue to negatively impact releases, as experienced with R3.12 in February. The project is actively performing an RCA to determine the source of defects as it pertains to releases/deployments. IV&V will continue to monitor this category in March.	
O	G	G	OJT and KT Sessions	The criticality rating for the OJT and KT Sessions category remains Green (low) for the February reporting period with no active findings.	
G	G	G	Targeted KT	The Targeted KT criticality rating remains Green (low) for the February reporting period. The Project Team has completed planning efforts for the KT sessions on Semantics Reporting and IDM tools, and has moved forward with the execution of the KT plan. IV&V will continue to monitor this category moving forward.	
G	G	G	Project Performance Metrics	The Project met its performance metrics for R3.12. IV&V will keep the criticality rating for this category a Green (low) and will continue to monitor this category moving forward.	
G	G	G	Organizational Maturity Assessment	The criticality rating for the Organization Maturity Assessment (OMA) will remain Green (low). Planning efforts for the next OMA (in March) is currently in progress.	
Y	Y	Y	Project Management	Quality issues that impact DDI activities continue to be an IV&V concern. The Project has implemented formal RCA processes to identify the cause of ongoing defects which should help to improve overall quality. BHA Leadership bandwidth also remains a concern for IV&V. The criticality rating for this category remains Yellow (medium) for the February reporting period. IV&V will continue to monitor this category in March.	



Executive Summary

As of the February 2021 reporting period, there are a total of ten open findings – four High Issues, two Medium Risks, and four Low Risks spread across the Sprint Planning, Release / Deployment Planning, Test Practice Validation, Targeted Knowledge Transfer, and Project Management assessment areas.





Assessment Categories

Throughout this project, IV&V will verify and validate activities performed in the following process areas:

- Sprint Planning
- User Story Validation
- Test Practice Validation
- Release / Deployment Planning
- On-the-Job Training (OJT) and Knowledge Transfer (KT) Sessions
- Targeted Knowledge Transfer (KT)
- Project Performance Metrics
- Organizational Maturity Assessment
- Project Management



Sprint Planning

#	Key Findings	Criticality Rating
8	Medium Risk - The BHA Technical Team bandwidth may not be adequate to meet the needs of the project, which could compromise project productivity. Due to lack of administrative approvals, the internal BHA efforts to post and fill technical positions have slowed. CAMHD is hopeful that the open IT Technical position will be posted in March. IV&V will continue to monitor.	M

Recommendations	Status
The Project should investigate mechanisms of increasing the bandwidth of the BHA Technical Team, either by adding resources through new hires, or vendor contracts.	In progress
The Project should assess, where possible, if there are responsibilities of the BHA Technical Team that can be reassigned to other project staff.	In progress
The Project should evaluate where process inefficiencies can be addressed and streamlined to possibly free up the BHA Technical Team's availability.	In progress
The Project should consider the formation of a first level M&O resource team to triage/address production defects in a timely manner, without disrupting new development work.	In progress
The Project should consider procurement of an online training toolset to support OCM and technical efforts to offset the need for in-person training.	Completed



Test Practice Validation

#	Key Findings	Criticality Rating
	High Issue – As a result of regression testing not being consistently performed, production releases are breaking and/or deprecating existing functionality in the production environment. R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release; one was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021.	
2	BHA initiated an RCA for the R3.12 defects to help with quality improvement and to ensure these same issues do not recur in future releases. Completion of the RCA is expected in early March.	H
	IV&V notes that DOH is working with Microsoft to schedule time in March/April to commence the efforts for regression testing automation. This functionality is expected to provide repeatable, automated regression test efforts for CAMHD and DDD in downstream releases. DOH is working to identify both internal DOH and external Microsoft resource participants for this effort.	

Recommendations		
Updating the regression test scripts to ensure consistency with system configuration.	Completed	
Modifying release schedules to allow for regression testing timeframes.	Completed	
 Planning releases by functionality type to avoid unnecessary repetitive work being performed in any given section of the solution. 	Completed	



Test Practice Validation (cont'd)

Recommendations	Status
 Performing regression testing after every release, or possibly every other release, or potentially tying regression tests to full solution upgrade releases. In addition, consider alternating the DDD and CAMHD scripts every other release. 	In Progress
 Modifying regression test scripts to start AFTER case creation, limiting the time it takes to execute. (This recommendation was for a point in time and is no longer valid.) 	Completed
Modifying the deployment scripts based on information gained from previous release deployments.	Completed
 Pursuing additional formal training in AzureDevOps for test automation at the earliest possible juncture and commence efforts to automate at least the 2 primary regression test scripts. 	Open
Consulting with RSM to determine how the 'interim testing processes' can be improved until such time that automated testing is available for repeatable and complete industry standard regression testing.	Completed
• Implementing 'hard' code freeze dates as well as test environment deployment dates to ensure that testing and deployment activities are not rushed.	Completed
IV&V recommends performing an RCA in collaboration with RSM for the continued concerns with regression testing efforts.	New
 Determine if current regression testing timeframes are adequate and if not, add more time to the pre- production regression test efforts for all release deployments. 	New



Release / Deployment Planning

#	Key Findings	Criticality Rating
19	High Issue - Due to on-going deployment processes and technical execution issues, the project may continue to encounter defects and challenges in meeting projected timelines for production and non-production deployments. R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021. BHA initiated an RCA for the R3.12 defects to help with quality improvement and to ensure these same issues do not recur in future releases. Completion of the RCA is expected in early March.	B

Recommendations	Status
 Develop a plan to institutionalize the execution of "Smoke Testing" for promotions to non-production and production environments. This will help to ensure that all components needed to test have been properly deployed prior to the actual execution of test activities. 	Open
 Work in collaboration with RSM to establish a transition plan for DOH to assume all deployment activities to ensure complete ownership of these processes. This should assist with consistency in approach and execution going forward. 	Open
As appropriate, consult with RSM on best practices that BHA could employ to support deployment.	In Progress



Release / Deployment Planning (cont'd)

Recommendations	Status
 Look at implementing 'hard' code freeze dates as well as test environment deployment dates to ensure that testing and deployment activities are not rushed. 	Completed
 Request the assistance of the RSM Solution Architect in reviewing and correcting issues associated with consistency of the configurations across environments, ensuring that the test environment is capable of testing ALL functions of any given release without the need for using multiple test environments. 	In Progress
 Request the assistance of the RSM Solution Architect in review of deployment scripts as a double check for accuracy and completeness prior to commencing deployment activities. 	In Progress
Ensure an operational and fully functional test environment is available to effectively conduct end-to-end regression testing prior to deploying a release to production.	Completed
The Project Team should consider evaluating potential changes to improve/enhance existing processes and communications to address current release/deployment shortfalls.	In Progress
 IV&V recommends performing an RCA in collaboration with RSM for the continued concerns surrounding environment differences. 	In Progress
 IV&V recommends updating the Project's Configuration Management Plan to address the current needs of the Project. This should include specific checklists geared at ensuring repeatable promotional processes by DOH. 	Open
 Due to an error prone process of 'cherry picking' what is and what is not ready for deployment, IV&V recommends that DOH and RSM collaborate to determine an improved manner for managing DOH environments. 	New



Release / Deployment Planning (cont'd)

#	#	Key Findings	Criticality Rating
18	8	High Issue - Due to consistent technical issues requiring escalation to Microsoft, some project efforts are being delayed. BHA continues to work with Microsoft on technical issues as they arise in the Government Community Cloud (GCC) instance. IV&V will continue to monitor this finding.	(1)

Recommendations	Status
IV&V recommends the project to continue to monitor the status of outstanding Microsoft tickets and to	In Progress
escalate the priority of these tickets as deemed necessary.	



Project Management

#	Key Findings	Criticality Rating
10	Medium Risk -The COVID-19 pandemic and related "stay at home" order could hinder project activities and negatively impact the project schedule and budget. As reported in January, there were no substantive changes observed for this finding in February. The Project continued to maintain its ability to operate with staff working remotely. IV&V continues to note that there may be potential future budget actions by the Governor due to projected State budget shortfalls, including furloughs that are planned to be re-evaluated in July. If realized, these actions could have negative effects on project funding.	M

Recommendations	Status
 IV&V recommends BHA to ramp up efforts to setup, train, and assist stakeholders on remote work devices and tools and make every effort to help them to become highly functional with remote access technology (e.g. MS Teams/Skype). 	Completed
 IV&V recommends the project and DOH create a detailed, documented risk mitigation strategy and plan that is reviewed regularly and revised to address the current state of the COVID-19 threat and related impacts over the next 6 to 12 months. 	In Progress
 IV&V recommends updates to the OCM Plan to include any new activities or updates to planned activities to aid the organization through this COVID-19 situation in the short and long term. 	Open



#	Key Findings	Criticality Rating
	High Issue - Due to multiple quality concerns, the project may continue to face impactful system defects. R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021.	Rating
15	BHA initiated an RCA for the R3.12 defects to help with quality improvement and to ensure these same issues do not recur in future releases. Completion of the RCA is expected in early March.	(H)
	IV&V notes that DOH is working with Microsoft to schedule time in March/April to commence the efforts for regression testing automation. This functionality is expected to provide repeatable, automated regression test efforts for CAMHD and DDD in downstream releases. DOH is working to identify both internal DOH and external Microsoft resource participants for this effort.	

Recommendations	Status
Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected.	In Progress
 Perform typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 	In Progress
Assign dedicated resources to provide oversight of CAMHD Fiscal Processes.	In Progress



Recommendations	
BHA and RSM to collaborate on the necessary revisions to the submitted design deliverables to increase level of detail and quality.	Completed
Monitor implemented improvements for effectiveness.	In Progress
Evaluate existing project staff skills and experience level to ensure they meet BHA support requirements.	Open
 IV&V recommends performing an RCA in collaboration with RSM after all future release deployments for continual quality improvement. 	New

#	Key Findings	Criticality Rating
13	Low Risk – PII/PHI data in non-production environments. There were no substantive changes for this finding in February. BHA is establishing a plan for managing its PHI/PII data in non-production environments. Based on continued delays, it is unclear when this important security activity will be completed.	L

Recommendations	Status
• IV&V recommends if production data is necessary in any non-production environment that DOH establishes a plan for effectively managing the security of the PII/PHI data, including the potential masking of data.	In Progress
 IV&V recommends that DOH mitigates this finding by minimizing and/or masking PHI/PII data in designated non-production environments. 	In Progress
 IV&V recommends DOH consider limiting the volume of environments and access necessary to support development work, which should help minimize this risk. 	Open



#	Key Findings	Criticality Rating
12	Low Risk – DDD Project resource shortages may have a continued negative effect on user adoption, training, and overall OCM activities. Training videos using the new toolset were nearing completion by the end of February. DOH is currently reviewing the drafts of the second set of videos and work is progressing well. IV&V will continue to monitor this finding until DDD has had sufficient time to determine the overall quality of the training work products and whether the new toolset is addressing user adoption and staffing shortages for these task efforts.	

Recommendations	Status
 IV&V recommends that BHA does as much as possible within its sphere of influence to increase user adoption and training. This includes procurement of the online training toolsets to offset the need for in-person training, and adding staff as needed to support OCM and technical efforts. 	In Progress
 IV&V recommends DOH perform a detailed investigation of the specific variations as to how the system is currently being used by the user community. Consequently, users would be provided with constructive feedback on how the system should be utilized where gaps exist. This will likely lead to additional refresher training to close identified system knowledge gaps. 	In Progress



#	Key Findings	Criticality Rating
14	Low Risk – Project unable to access activity logs. BHA continued this effort in February despite a workaround being necessary from Microsoft due to a layering issue. Based on continued delays, it is unclear when this important security activity will be completed. IV&V will continue to monitor this finding.	L

Recommendations	Status
 IV&V recommends that DHS continues to collaborate with Microsoft until the activity logging feature is available in all BHA non-production environments. 	In Progress



#	Key Findings	Criticality Rating
17	Low Risk - The bandwidth of CAMHD Leadership is being hampered by planning tasks and activities for assessing project expansion to other divisions. CAMHD Leadership continued to spend upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of dedication to this effort is certain to continue to increase in the coming months. IV&V will continue to monitor this finding.	L

Recommendations	Status
 IV&V recommends CAMHD look for opportunities to augment the management staffing for planning Phase 4 and M&O work. 	In Progress



#	Key Findings	Criticality Rating
20	New Preliminary Concern – The pending RSM contract expiration will require BHA to perform transition of the D365 solution to the State prior to contract end. The RSM contract for Phase 3 is currently planned to complete in September 2021. BHA will need to ensure that it has all knowledge transfer and is fully capable of managing all aspects of supporting and maintaining the D365 solution without vendor support until at least the Phase 4 expansion effort is procured and initiated. The Phase 4 effort is currently expected to commence late in the 4th quarter of 2021, or early in the first quarter of 2022. The Phase 4 procurement scope is planned to include additional DD&I activities, as well as M&O support activities.	N/A



Project Performance Metrics

Metric	Description	IV&V Observations	IV&V Updates
Velocity	 Review and validate the velocity data as reported by the project Verify the project is on pace to hit the total target number of US/USP for Phase 3 	February – Available velocity was estimated at 300 user story points for R3.12. A total of 251.27 USPs (83%) were completed (17.77 in an MSD on 1/15/2021, and 233.5 in R3.12 on 2/14/2021). IV&V notes that RSM includes USP counts from Mid Sprint Deployments prior to a planned release as component of the planned release. Overall, the cumulative Phase 3 targeted USPs through R3.12 was planned for 1,038. The cumulative completed USPs total is currently 1349.3.	N/A

Project Performance Metrics (cont'd.)

Metric	Description	IV&V Observations	IV&V Updates
Defect Metrics	 Understand and track the following: Defects by category (bug fixes) US Points assigned to defects in a release vs US Points assigned to planned US in a release 	 February – R3.12 was comprised of 233.5 USPs that were released to production. 83% of the total USPs were associated with planned user stories and requests. 17% of the total USPs were associated with defects from the backlog. 	N/A

Organizational Maturity Assessment

Measure IV&V Observations

The Organizational Maturity Assessment (OMA) is updated on a bi-monthly basis. IV&V currently planning for the next OMA in March 2021.



Appendix A: IV&V Rating Scales

Appendix AIV&V Rating Scales

This appendix provides the details of each finding and recommendation identified by IV&V. Project stakeholders are encouraged to review the findings and recommendations log details as needed.

- See Findings and Recommendations Log (provided under separate cover)
- IV&V Assessment Category Rating Definitions

The assessment category is under control and the current scope can be delivered within the current schedule.

The assessment category's risks and issues have been identified, and mitigation activities are effective. The overall impact of risk and issues is minimal.

The assessment category is proceeding according to plan (< 30 days late).

The assessment category is under control but also actively addressing resource, schedule or scope challenges that have arisen. There is a clear plan to get back on track.



The assessment category's risk and/or issues have been identified, and further mitigation is required to facilitate forward progress. The known impact of potential risks and known issues are likely to jeopardize the assessment category. Schedule issues are emerging (> 30 days but < 60 days late).

Project Leadership attention is required to ensure the assessment category is under control.

The assessment category is not under control as there are serious problems with resources, schedule, or scope. A plan to get back on track is needed.



The assessment category's risks and issues pose significant challenges and require immediate mitigation and/or escalation. The project's ability to complete critical tasks and/or meet the project's objectives is compromised and is preventing the project from progressing forward.

Significant schedule issues exist (> 60 days late). Milestone and task completion dates will need to be re-planned. Executive management and/or project sponsorship attention is required to bring the assessment category under control.



Appendix A

Finding Criticality Ratings

Criticality Rating	Definition
•	A high rating is assigned if there is a possibility of substantial impact to product quality, scope, cost, or schedule. A major disruption is likely, and the consequences would be unacceptable. A different approach is required. Mitigation strategies should be evaluated and acted upon immediately.
M	A medium rating is assigned if there is a possibility of moderate impact to product quality, scope, cost, or schedule. Some disruption is likely, and a different approach may be required. Mitigation strategies should be implemented as soon as feasible.
•	A low rating is assigned if there is a possibility of slight impact to product quality, scope, cost, or schedule. Minimal disruption is likely, and some oversight is most likely needed to ensure that the risk remains low. Mitigation strategies should be considered for implementation when possible.



Appendix B: Inputs

Appendix B Inputs

This appendix identifies the artifacts and activities that serve as the basis for the IV&V observations.

Meetings attended during the February 2021 reporting period:

- Daily Scrum Meetings (selected)
- 2. Twice Weekly RSM Issues Meeting
- 3. Weekly BHA-ITS Project Status Meeting
- 4. Bi-Weekly Check-in: CAMHD
- Bi-Weekly Check-in: DDD
- 6. BHA IAPDU Planning Meeting
- 7. IV&V Draft IV&V Status Review Meeting with DOH
- IV&V Draft IV&V Status Review Meeting with RSM and DOH

Eclipse IV&V® Base Standards and Checklists

Artifacts reviewed during the February 2021 reporting period:

- Daily Scrum Notes (selected)
- 2. Twice Weekly Issues Meeting Notes (selected)
- 3. Root Cause Analysis Worksheet





Appendix C: Project Trends

Appendix C Project Trends

Trend:	Overall	Projec	t Health	1						
Process Area					2020	-2021				
Process Area	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb
User Story Validation										
Test Practice Validation										
Sprint Planning										
Release / Deployment Planning										
OJT and KT Sessions										
Targeted KT										
Project Performance Metrics										
Organizational Maturity Metrics										
General Project Management										
Total Open Findings	6	6	6	7	7	10	11	11	10	11
Issue - high	0	0	0	0	0	0	0	0	4	4
Issue - medium	0	0	0	1	2	2	4	4	0	0
Issue - low	1	1	1	0	0	0	0	0	0	0
Risk - high	1	0	1	0	0	0	0	0	0	0
Risk - medium	0	2	2	3	3	3	2	2	2	2
Risk - low	3	2	1	0	0	0	3	3	4	4
Preliminary Concern	1	1	1	3	3	5	2	2	0	1



Solutions that Matter

ID No	Identified Date	Title	Observation	Significance	Recommendation	Updates	Process Area	Finding Type	Priority	Status	Closure Reason	Risk Owner
1.000	12/31/2019	and adoption of generally accepted agile best practices.	overall approach to agile software development: - IV&V acknowledges that the project is now planning three sprints outs, however, it appears that only a "high-level" sprint planning roadmap has been produced, and it is unclear exactly how the project is targeting	While having a high level roadmap is good, the project should be able to identify what feature enhancements will be targeted for each planned release. This roadmap will help the project manage scope and productivity. Relatedly, the "definition done" is an important artifact to ensure that the project is successful. Otherwise, the project will struggle to prioritize requests/enhancements and manage scope.	As much as possible, the project should identify what feature enhancements will be targeted for each Release and should clearly map out the roadmap out through the last Phase 3 release in September 2020. Additionally, the project should clearly define "Done" to ensure the project team is working towards the same goal and increase opportunities for success. Having a clear "definition of done" will help provide the project with guidance on how to stay within scope.	01/31/2020 - IV&V is closing this concern, and will be tracking items related to Definition of Done, roadmap, resourcing, and backlog grooming in new, separate findings.	Sprint Planning	Concern	N/A	Closed	Due to multiple new items being tracked at a more granular level, this item has been closed.	V Ramesh
2.000		As a result of regression testing not being consistently performed, production releases are both breaking and deprecating existing functionality in the production environment.	R3.3 introduced a defect that deprecated features in production specific to Integrated Support and Life Trajectory functionality. DDD has informed IV&V that there are other examples of functionality being deprecated after a release, some of which are still being investigated. As of this report, IV&V has not evaluated the project's root	Thorough vetting and validation of regression test cases is necessary to prevent both defects and the deprecation of production functionality when a release is pushed live. When defects occur in production, the project should follow a defined and repeatable process for determining the root cause of the problem.	regression testing timeframes - Completed 3. Grouping releases by functionality type	02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release; one was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021. BHA initiated an RCA for the R3.12 defects to help with quality improvement and to ensure these same issues do not recur in future releases. Completion of the RCA is expected in early March. IV&V notes that DOH is working with Microsoft to schedule time in March/April to commence the efforts for regression testing automation. This functionality is expected to provide repeatable, automated regression test efforts for CAMHD and DDD in downstream releases. DOH is working to identify both internal DOH and external Microsoft resource participants for this effort. 01/31/2021 - A Mid-Sprint Deployment to production was released on 1/15/21 to address high priority defects. Consistent with previous releases, issues in the production environment were observed and existing functionality was deprecated (e.g., SIS assessment scores). Although root cause analysis is ongoing, these	Test Practice Validation	Issue	High	Open		D Macdonald

3.000	12/31/2010	Usage of open source JavaScript	IV&V learned in December 2019	Open source tools and	IV&V recommends BHA work to establish a	08/31/2020 - IV&V is unaware of any additional	Targeted KT	Risk	Low	Closed	RSM has	ln .
3.000	12/31/2019	framework for development and	that the Calculator 3.0 functionality	frameworks offer organizations	reliable and repeatable process for	KT gaps being identified by DOH, and as such, is	rangeteu Ki	THISK	LOW	Ciosca		Macdonald
		ongoing maintenance of Calculator 3.0	1	great opportunities to build	keeping abreast of communal updates and						held several	Iviacaonaia
		requires BHA to take a proactive	JavaScript framework. As this	and configure customized	support opportunities for a new suite of						KT sessions	
		approach to support and security.	framework is relatively new, the	solutions at lower costs than	tools - Completed	07/31/2020 - The Project resolved the majority					for this	
			open source support community is	through software purchase or	IV&V recommends BHA continue to hold	of the outstanding Calculator 3.0 defects during					technology	
			small. IV&V's concerns include:	licensing. However, open	targeted KT sessions with RSM on	July which was implemented in the mid-sprint					and	
				source tools and frameworks	maintaining Calculator 3.0 via a suite of	release on 7/17/2020. The final Calculator 3.0					functionality,	
			for Vue.JS	often do not come with	tools, and determine what additional	Knowledge Transfer session was conducted on					and DOH	
			- The project's understanding of	support models, other than	skillsets, training, and/or resources are	7/17/2020. IV&V recommends BHA to identify					staff have	
			any known vulnerabilities with	those offered through the	needed to support BHA's long-term	and communicate any additional KT gaps to					stated that it	
			Vue.JS, and development of a	tool's community. Because of	ownership of Calculator 3.0 - Completed	RSM during the month of August. If no					was well	
			process to remain current on	this, the organization bears the		additional needs are identified, IV&V will close					received.	
			vulnerabilities discovered by the	weight of seeking out reliable		this finding.						
			support community.	help and support, as well as		06/30/2020 - The project continued to focus						
			- The RSM lead for Calculator 3.0	much take a proactive		attention on the Calculator 3.0 defects during						
			went on extended parental leave in	approach to security and		the month of June. RSM conducted another						
			December 2019	identifying any vulnerabilities		Calculator 3.0 Knowledge Transfer session on						
			IV&V acknowledges that BHA has	in the tools.		6/26/2020 and scheduled a final session for						
			downloaded Vue.JS to start getting			7/17/2020.						
			familiar with it.									
						05/31/2020 - The project continued to focus						
						attention on the Calculator 3.0 user stories and						
						defects during the month of May. RSM						
						conducted another Calculator 3.0 Knowledge						
						Transfer session on 5/29/2020 which IV&V						
E 000	1/21/2020	Due to the project set fellowing -	Thoro have been covered defect-	A complete up to data and	IVA/ recommends decimenting	attended. This session included the new C3.0	Rologeo / Dorder meent	Issue	Madir	Clasad	Voy finding	D
5.000	1/31/2020	Due to the project not following a	There have been several defects	A complete, up to date, and	IVV recommends documenting	12/31/2020 - IV&V has closed this issue as the	Release/Deployment	Issue	Medium	Closed	Key finding	D Macdonald
5.000	1/31/2020	detailed deployment script, the	pushed to production with Phase 3	documented deployment	deployment scripts for both the patch	12/31/2020 - IV&V has closed this issue as the related recommendations below has been	Release/Deployment Planning	Issue	Medium	Closed	has been	D Macdonald
5.000	1/31/2020	detailed deployment script, the project may continue to experience	pushed to production with Phase 3 releases. Some of the defects	documented deployment script is needed to ensure the	deployment scripts for both the patch method and the full solution upgrade	12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding		Issue	Medium	Closed	has been addressed	D Macdonald
5.000	1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment	pushed to production with Phase 3 releases. Some of the defects introduced to production have been	documented deployment script is needed to ensure the repeatability and stability of	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the	12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing		Issue	Medium	Closed	has been addressed and	D Macdonald
5.000	1/31/2020	detailed deployment script, the project may continue to experience	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental	documented deployment script is needed to ensure the repeatability and stability of DOH's production	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that	12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution		Issue	Medium	Closed	has been addressed and proposed	D Macdonald
5.000	1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the	12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues.		Issue	Medium	Closed	has been addressed and proposed IV&V	D Macdonald
5.000	1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several	12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to		Issue	Medium	Closed	has been addressed and proposed IV&V recommenda	D Macdonald
5.000	1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to	12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine		Issue	Medium	Closed	has been addressed and proposed IV&V recommenda tions have	D Macdonald
5.000	1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary	12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the		Issue	Medium	Closed	has been addressed and proposed IV&V recommenda tions have been	D Macdonald
5.000	1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to	12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine		Issue	Medium	Closed	has been addressed and proposed IV&V recommenda tions have	D Macdonald
5.000	1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable.	12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a		Issue	Medium	Closed	has been addressed and proposed IV&V recommenda tions have been completed. A	D Macdonald
5.000	1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer	12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a		Issue	Medium	Closed	has been addressed and proposed IV&V recommenda tions have been completed. A subsequent	D Macdonald
5.000	1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of	12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment		Issue	Medium	Closed	has been addressed and proposed IV&V recommenda tions have been completed. A subsequent finding #19	D Macdonald
5.000	1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the	12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as		Issue	Medium	Closed	has been addressed and proposed IV&V recommenda tions have been completed. A subsequent finding #19 has been	D Macdonald
5.000	1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner	12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in		Issue	Medium	Closed	has been addressed and proposed IV&V recommenda tions have been completed. A subsequent finding #19 has been created to	D Macdonald
5.000	1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment	12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the deployment, resulting in contacts being		Issue	Medium	Closed	has been addressed and proposed IV&V recommenda tions have been completed. A subsequent finding #19 has been created to address on-	D Macdonald
5.000	1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment	12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the deployment, resulting in contacts being deprecated from the Circle of Support in		Issue	Medium	Closed	has been addressed and proposed IV&V recommenda tions have been completed. A subsequent finding #19 has been created to address ongoing	D Macdonald
5.000	1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment	12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. It is unclear if any other deployment		Issue	Medium	Closed	has been addressed and proposed IV&V recommenda tions have been completed. A subsequent finding #19 has been created to address ongoing deployment	D Macdonald
5.000	1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment	12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. It is unclear if any other deployment issues may have also contributed to the new		Issue	Medium	Closed	has been addressed and proposed IV&V recommenda tions have been completed. A subsequent finding #19 has been created to address ongoing deployment processes	D Macdonald
5.000	1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment	12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. It is unclear if any other deployment issues may have also contributed to the new defects. Deployment corrections were applied		Issue	Medium	Closed	has been addressed and proposed IV&V recommenda tions have been completed. A subsequent finding #19 has been created to address ongoing deployment processes and technical	D Macdonald
5.000	1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment	12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. It is unclear if any other deployment issues may have also contributed to the new defects. Deployment corrections were applied in a mid sprint release on 11/27/2020. Based		Issue	Medium	Closed	has been addressed and proposed IV&V recommenda tions have been completed. A subsequent finding #19 has been created to address ongoing deployment processes and technical execution	D Macdonald
5.000	1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, or deployment notes, are	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment	12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. It is unclear if any other deployment issues may have also contributed to the new defects. Deployment corrections were applied in a mid sprint release on 11/27/2020. Based on the recurrence of this finding, IV&V has		Issue	Medium	Closed	has been addressed and proposed IV&V recommenda tions have been completed. A subsequent finding #19 has been created to address ongoing deployment processes and technical execution	D Macdonald
5.000	1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, or deployment notes, are being utilized by BHA for	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment	12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. It is unclear if any other deployment issues may have also contributed to the new defects. Deployment corrections were applied in a mid sprint release on 11/27/2020. Based on the recurrence of this finding, IV&V has changed this Risk to an Issue and will continue to monitor until resolved. 10/31/2020 - The RSM and DOH Teams have		Issue	Medium	Closed	has been addressed and proposed IV&V recommenda tions have been completed. A subsequent finding #19 has been created to address ongoing deployment processes and technical execution	D Macdonald
5.000	1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, or deployment notes, are being utilized by BHA for	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment	12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. It is unclear if any other deployment issues may have also contributed to the new defects. Deployment corrections were applied in a mid sprint release on 11/27/2020. Based on the recurrence of this finding, IV&V has changed this Risk to an Issue and will continue to monitor until resolved. 10/31/2020 - The RSM and DOH Teams have collaborated to develop a detailed Production		Issue	Medium	Closed	has been addressed and proposed IV&V recommenda tions have been completed. A subsequent finding #19 has been created to address ongoing deployment processes and technical execution	D Macdonald
5.000	1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, or deployment notes, are being utilized by BHA for	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment	12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. It is unclear if any other deployment issues may have also contributed to the new defects. Deployment corrections were applied in a mid sprint release on 11/27/2020. Based on the recurrence of this finding, IV&V has changed this Risk to an Issue and will continue to monitor until resolved. 10/31/2020 - The RSM and DOH Teams have		Issue	Medium	Closed	has been addressed and proposed IV&V recommenda tions have been completed. A subsequent finding #19 has been created to address ongoing deployment processes and technical execution	D Macdonald

6.000	'Definition of Done", which could challenge the project's ability to fully achieve the goals of Phase 3.	functionality/features are prioritized for each sprint, and throughout Phase 3.	The 'Definition of Done" document guides the Project's vision, business, and technical goals that are important inputs for stakeholders to develop a Roadmap for Phase 3. Without the 'Definition of Done' document, the project is likely to struggle to prioritize proposed functionality/features which may be equally important but are at odds with each other.	available resources and define "Done" as a percentage of the identified priority list with room for flexibility to add any other features/enhancements that will be identified during Phase 3.	02/29/2020 - The project created and documented the Phase 3 Definition of Done and socialized it in February. IV&V recommends the project continually review and update the Definition of Done, adjusting as/if necessary. IV&V will continue to monitor the project's adherence to Definition of Done and progress against it but is closing out this concern as of the February report.		Concern	N/A	Closed	Definition of Done completed and socialized.	V Ramesh
7.000		The backlog of defects, requests, and user stories continues to grow. Currently, there are approximately 429 defects and requests, of which almost 200 have a status of 'New'. IVV notes that a large percentage of the backlogged work items do not have user story points estimated. Many of the items listed in the backlog are old, and some may have had needs or requirements change over time or may now be obsolete. IV&V notes that DDD and CAMHD have initiated this effort and agreed to prioritize grooming the backlog by the end of February.	A comprehensive, up-to-date backlog is a primary tenet of agile software development. If a backlog is carrying work items that may not ever be completed for any reason, they should be removed from the backlog to ensure its viability.	are not yet fully defined, readying them for configuration or developer resources. To the extent feasible, BHA should involve RSM SMEs in this process, if only for the interim to get "caught up" on grooming efforts. (Closed) VV recommends that the project consider utilizing an age-based methodology for the deprecation of 'older' user stories in the backlog that may no longer be applicable or needed by the Product Owners and	06/30/2020 - IV&V has observed for another month that the project continues to groom the backlog. As a result, we are closing this finding. 05/31/2020 - The project team has determined the backlog grooming effort has caught up, as details for release 3.9 are completed and 3.10 is near completion. IV&V will keep this finding open for an additional month to validate that the backlog continues to be groomed as new stories and defects are identified. Efforts to keep the backlog groomed should take place each month so that release planning efforts are not delayed. 04/30/2020 - The project reported that 97% of the original backlog has been estimated at this time. That said, CAMHD has determined that there are several older, and possibly no longer necessary user stories in the backlog that are candidates for deletion. IV&V will keep this finding open and will re-assess it for impact during the month of May. 03/31/2020 - IV&V validates that the backlog grooming effort has made great progress, however it is still in progress. The revised target date for completion was most recently	Project Management	Risk	Low	Closed	The project has demonstrate d they are consistently grooming the backlog.	D Macdonald

8.000		The BHA Technical Team bandwidth may not be sufficient to meet the needs of the project, which could compromise project productivity.	role that is critical to project success. Currently, the responsibilities associated with the	The BHA Technical Team leads the efforts of all technical DOH staff on the project. As such, the Team's time is both extremely valuable and scarce. If the Team's expected workload exceeds bandwidth, the project could experience bottlenecks. Optimization of the BHA Technical Team's time is to the benefit of the project and plays a critical role in the project's ability to hit performance targets and achieve the Phase 3 definition of done.	The Project should investigate mechanisms of increasing the bandwidth of the BHA Technical Team, either by adding resources through new hires, or vendor contracts. The Project should assess, where possible, if there are responsibilities of the BHA Technical Team that can be reassigned to other project staff. The Project should evaluate where process inefficiencies can be addressed and streamlined to possibly free up the BHA Technical Team's availability. The Project should consider the formation of a first level M&O resource team to triage/address production defects in a timely manner, without disrupting new development work. The Project should consider procurement of an online training toolset to support OCM and technical efforts to offset the need for in-person training - COMPLETED.	02/28/2021 - Due to lack of administrative approvals, the internal BHA efforts to post and fill technical positions have slowed. CAMHD is hopeful that the open IT Technical position will be posted in March. IV&V will continue to monitor. 01/31/2021 - Due to internal DOH processes, the recruiting announcement for CAMHD's open IT Technician position was delayed until February. IV&V will continue to monitor this finding. IV&V notes that the RSM Team continued to provide essential support during January, alleviating some of the bandwidth concerns expressed by DOH to meet crucial project needs. Due to RSM resource levels being significantly reduced in March, the balance of agile releases will also be reduced in scope. 12/31/2020 - BHA stated that although most vacant positions cannot be filled at this time, they have approval to fill a vacant IT Technician position. IV&V will continue to monitor this finding. 11/30/2020 - There were no substantive changes to this finding in November. IV&V will continue to monitor. 10/31/2020 - There were no substantive	Sprint Planning	Risk	Medium	Open		D Macdonald
9.000	, ,	The lack of a Product Roadmap that provides direction on the top product features to be delivered in the near term (next 3 months), midterm, and long term could have an adverse impact on the Project's scope and schedule.	BHA does not have a single, definitive Product Roadmap for Phase 3 that addresses the functionalities, features, and / or enhancements to be built in order to fully address BHA's business needs. IV&V met with RSM and BHA on this topic in January, and notes that the project is actively working to address this concern.	A Roadmap is a tool that guides an agile project on what functionalities/features are targeted to be built and released and when users can have access to these functionalities. Without a defined Roadmap the project may not be able to effectively scope the top features to be released within Phase 3 and ensure the correct resources are available to accomplish the goal of each sprint and the Phase.	IV&V understands that the Project is in the process of creating a Short Term; Mid Term, and Long Term Roadmap. IV&V recommends the Project complete this by the end of February 2020 to understand if there are any constraints (resources, budget) that may hinder the project from releasing the needed functionalities/features targeted for Phase 3 as documented in the Definition of Done.	02/29/2020 - In February, the project further defined the Phase 3 Product Roadmap and aligned it with the Phase 3 Definition of Done. IV&V recommends the project continually review and update both the Product Roadmap and Definition of Done, adjusting as necessary. IV&V will continue to monitor the project's adherence to the Product Roadmap and progress against it but is closing out this concern as of the February report.	Project Management	Concern	N/A	Closed	Product Roadmap aligned with Definition of Done	V Ramesh

10,000	3/31/2020	The COVID-19 nandemic and the	On 3/23/2020, the Governor issued	DOH stakeholder participation	- IV&V recommends BHA to ramp up	02/28/2021 - As reported in January, thoro	Project Management	Rick	Madium	Open		n
10.000		related "stay at home" order could hinder project activities and negatively impact the project schedule and budget.	a "stay at home, work from home order" that has reduced state departments ability to be fully functional as the large majority of state workers will be required to work from home/remotely at least until the end of April and some offices may be completely shut down until that time as well. Unclear if the order will extend beyond that date.	by required remote work by DOH and SI staff, but also by the flood of activities that could occur as the department could become overwhelmed processing and providing services due to the resulting economic impacts to citizens. Some stakeholders may be unable (due to stricter shutdown policies) or unwilling to perform these activities during this chaotic time. Planned SI on-site visits will also likely be changed to	- IV&V recommends updates to the OCM Plan to include any new activities or updates to planned activities to aid the organization through this COVID-19	02/28/2021 - As reported in January, there were no substantive changes observed for this finding in February. The Project continued to maintain its ability to operate with staff working remotely. IV&V continues to note that there may be potential future budget actions by the Governor due to projected State budget shortfalls, including furloughs that are planned to be re-evaluated in July. If realized, these actions could have negative effects on project funding. 01/31/2021 - No substantive changes were observed in January. The project continued to maintain its ability to operate with staff working remotely. As previously reported, key project staff continue to have responsibility for participating in non-project activities to support the COVID-19 crisis. The HI Governor announced in late December that furloughs will be delayed due to the potential of the COVID Relief bill funding from the federal government. IV&V continues to note that there may also be potential future budget actions by the Governor due to projected State budget shortfalls, including furloughs that are planned to be re-evaluated in July. If realized, these		Risk	Medium	Open		D Macdonald
11.000		l'	during May where the code promoted to production did not fully meet all requirements of associated user stories for CAMHD Progress Notes. The components that were developed and	If all requirements within a functional design are not met, users could experience the inability to complete required processes, resulting in incomplete data collection and potential issues in service delivery.	IV&V recommends (and DOH has commenced) conducting technical design reviews for complex user stories prior to development to ensure designs are complete and all requirements associated with the design are met. IV&V observed this activity has been implemented by DOH in the month of May.	actions could have negative effects on project O7/31/2020 - The Project continues to to spend additional time on the designs of complex user stories during June to ensure requirements and user story components were fully captured in design sessions. This process change has proven successful, and as such, IV&V recommends closing this concern. O6/30/2020 - IV&V acknowledges the Project Team continued to spend additional time on the designs of complex user stories during June to ensure requirements and user story components were fully captured in design sessions. IV&V will continue to monitor in July.		Concern		Closed	This process change to spend extra time on the design of complex user stories to ensure that all requirement s are represented has proven to be successful.	

12.000	7/21/2020 DDD Broi	ject resource shortages may	The user adoption and training	The significance and impact of	IV&V recommends that BHA does as much	02/28/2021 - Training videos using the new	Project Management	Risk	Low	Open	ln l
12.000		ontinued negative effect on	efforts are hampered based on	OCM can never be		toolset were nearing completion by the end of	Project Management	NISK	LOW	Ореп	Macdonald
		ption, training, and overall	staffing shortages. DDD has stated		increase user adoption and training. This	February. DOH is currently reviewing the drafts					Iviacuonaiu
	OCM acti		that its users have been found to	practice that best that all staff	includes procurement of the online	of the second set of videos and work is					
	OCIVI acti	ivities.	not be utilizing the system to its	utilize the solution in the same		progressing well. IV&V will continue to monitor					
			fullest extent in terms of system	manner. Variations in how the		this finding until DDD has had sufficient time to					
			workflow, provide their insights and	system is utilized by its users is	needed to support OCM and technical	determine the overall quality of the training					
			input, follow up, etc. To assist in	likely to cause variations in	efforts.	work products and whether the new toolset is					
			OCM activities, DDD has defined	data collection and analytical	IV&V recommends DOH perform a detailed	· · · · · · · · · · · · · · · · · · ·					
			the need for an interactive training	efforts using the data		shortages for these task efforts.					
			tool to support Inspire.	collected.		01/31/2021 - Training design activities using					
						the interactive training toolset commenced in					
					would be provided with constructive	January and has attained good progress. The					
					feedback on how the system should be	use of this tool is expected to provide some					
					utilized where gaps exist. This will likely	bandwidth relief for DDD staff members					
					lead to additional refresher training to	responsible for onboarding new staff members					
					close identified system knowledge gaps.	and providers, and to provide refresher training					
						to existing staff members. IV&V will continue to					
						monitor this finding					
						12/31/2020 - The contract to procure the					
						interactive training toolset for onboarding new					
						staff members and providers and to provide					
						refresher training to existing staff members					
						was successfully executed. Planning for the					
						design of the necessary training will commence					
						in January. Additionally, DDD has secured a					
						contract for temporary Report Writing services.					
13.000		lata in non-production	IV&V has been made aware that	Failure to secure PII/PHI data	IV&V recommends if production data is	02/28/2021 - There were no substantive	Project Management	Risk	Low	Open	D
	environm	nents	PII/PHI data currently exist in a non-	leaves the organization open	necessary in any non-production	changes for this finding in February. BHA is					Macdonald
			production environment to meet	to highly targeted social	environment that DOH establishes a plan	establishing a plan for managing its PHI/PII data					
			project needs. Generally this is not	engineering attacks, heavy		in non-production environments. Based on					
			a good security practice as the	regulatory fines, and loss of	PII/PHI data, including the potential	continued delays, it is unclear when this			1		
				I	l .						
			presence of PII/PHI data in non-	client trust and loyalty.	masking of data.	important security activity will be completed.					
			production environments increases	client trust and loyalty.	masking of data. IV&V recommends that DOH mitigates this	important security activity will be completed. 01/31/2021 - No substantive changes were					
1 1			production environments increases the potential for theft, loss or	client trust and loyalty.	masking of data. IV&V recommends that DOH mitigates this finding by removing and/or masking any	important security activity will be completed. 01/31/2021 - No substantive changes were observed in January. BHA is still in the process					
			production environments increases the potential for theft, loss or exposure thus increasing the	client trust and loyalty.	masking of data. IV&V recommends that DOH mitigates this finding by removing and/or masking any PHI/PII data in its non-production	important security activity will be completed. 01/31/2021 - No substantive changes were observed in January. BHA is still in the process of establishing a plan for managing PHI/PII					
			production environments increases the potential for theft, loss or exposure thus increasing the organization's risk. Failure to secure	client trust and loyalty.	masking of data. IV&V recommends that DOH mitigates this finding by removing and/or masking any PHI/PII data in its non-production environments.	important security activity will be completed. 01/31/2021 - No substantive changes were observed in January. BHA is still in the process of establishing a plan for managing PHI/PII data. This effort remains anticipated to					
			production environments increases the potential for theft, loss or exposure thus increasing the organization's risk. Failure to secure PII/PHI data leaves the organization	client trust and loyalty.	masking of data. IV&V recommends that DOH mitigates this finding by removing and/or masking any PHI/PII data in its non-production environments. NEW - IV&V recommends DOH consider	important security activity will be completed. 01/31/2021 - No substantive changes were observed in January. BHA is still in the process of establishing a plan for managing PHI/PII data. This effort remains anticipated to commence in February, after Release 3.12 is					
			production environments increases the potential for theft, loss or exposure thus increasing the organization's risk. Failure to secure PII/PHI data leaves the organization open to highly targeted social	client trust and loyalty.	masking of data. IV&V recommends that DOH mitigates this finding by removing and/or masking any PHI/PII data in its non-production environments. NEW - IV&V recommends DOH consider limiting the volume of environments and	important security activity will be completed. 01/31/2021 - No substantive changes were observed in January. BHA is still in the process of establishing a plan for managing PHI/PII data. This effort remains anticipated to commence in February, after Release 3.12 is completed. IV&V will continue to monitor this					
			production environments increases the potential for theft, loss or exposure thus increasing the organization's risk. Failure to secure PII/PHI data leaves the organization open to highly targeted social engineering attacks, heavy	client trust and loyalty.	masking of data. IV&V recommends that DOH mitigates this finding by removing and/or masking any PHI/PII data in its non-production environments. NEW - IV&V recommends DOH consider limiting the volume of environments and access necessary to support development	important security activity will be completed. 01/31/2021 - No substantive changes were observed in January. BHA is still in the process of establishing a plan for managing PHI/PII data. This effort remains anticipated to commence in February, after Release 3.12 is completed. IV&V will continue to monitor this finding.					
			production environments increases the potential for theft, loss or exposure thus increasing the organization's risk. Failure to secure PII/PHI data leaves the organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client	client trust and loyalty.	masking of data. IV&V recommends that DOH mitigates this finding by removing and/or masking any PHI/PII data in its non-production environments. NEW - IV&V recommends DOH consider limiting the volume of environments and	important security activity will be completed. 01/31/2021 - No substantive changes were observed in January. BHA is still in the process of establishing a plan for managing PHI/PII data. This effort remains anticipated to commence in February, after Release 3.12 is completed. IV&V will continue to monitor this finding. 12/31/2020 - BHA is still in the process of					
			production environments increases the potential for theft, loss or exposure thus increasing the organization's risk. Failure to secure PII/PHI data leaves the organization open to highly targeted social engineering attacks, heavy	client trust and loyalty.	masking of data. IV&V recommends that DOH mitigates this finding by removing and/or masking any PHI/PII data in its non-production environments. NEW - IV&V recommends DOH consider limiting the volume of environments and access necessary to support development	important security activity will be completed. 01/31/2021 - No substantive changes were observed in January. BHA is still in the process of establishing a plan for managing PHI/PII data. This effort remains anticipated to commence in February, after Release 3.12 is completed. IV&V will continue to monitor this finding. 12/31/2020 - BHA is still in the process of establishing a plan for managing PHI/PII data					
			production environments increases the potential for theft, loss or exposure thus increasing the organization's risk. Failure to secure PII/PHI data leaves the organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client	client trust and loyalty.	masking of data. IV&V recommends that DOH mitigates this finding by removing and/or masking any PHI/PII data in its non-production environments. NEW - IV&V recommends DOH consider limiting the volume of environments and access necessary to support development	important security activity will be completed. 01/31/2021 - No substantive changes were observed in January. BHA is still in the process of establishing a plan for managing PHI/PII data. This effort remains anticipated to commence in February, after Release 3.12 is completed. IV&V will continue to monitor this finding. 12/31/2020 - BHA is still in the process of establishing a plan for managing PHI/PII data and plans to complete this effort in February					
			production environments increases the potential for theft, loss or exposure thus increasing the organization's risk. Failure to secure PII/PHI data leaves the organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client	client trust and loyalty.	masking of data. IV&V recommends that DOH mitigates this finding by removing and/or masking any PHI/PII data in its non-production environments. NEW - IV&V recommends DOH consider limiting the volume of environments and access necessary to support development	important security activity will be completed. 01/31/2021 - No substantive changes were observed in January. BHA is still in the process of establishing a plan for managing PHI/PII data. This effort remains anticipated to commence in February, after Release 3.12 is completed. IV&V will continue to monitor this finding. 12/31/2020 - BHA is still in the process of establishing a plan for managing PHI/PII data					
			production environments increases the potential for theft, loss or exposure thus increasing the organization's risk. Failure to secure PII/PHI data leaves the organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client	client trust and loyalty.	masking of data. IV&V recommends that DOH mitigates this finding by removing and/or masking any PHI/PII data in its non-production environments. NEW - IV&V recommends DOH consider limiting the volume of environments and access necessary to support development	important security activity will be completed. 01/31/2021 - No substantive changes were observed in January. BHA is still in the process of establishing a plan for managing PHI/PII data. This effort remains anticipated to commence in February, after Release 3.12 is completed. IV&V will continue to monitor this finding. 12/31/2020 - BHA is still in the process of establishing a plan for managing PHI/PII data and plans to complete this effort in February after Release 3.12. IV&V will continue to					
			production environments increases the potential for theft, loss or exposure thus increasing the organization's risk. Failure to secure PII/PHI data leaves the organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client	client trust and loyalty.	masking of data. IV&V recommends that DOH mitigates this finding by removing and/or masking any PHI/PII data in its non-production environments. NEW - IV&V recommends DOH consider limiting the volume of environments and access necessary to support development	important security activity will be completed. 01/31/2021 - No substantive changes were observed in January. BHA is still in the process of establishing a plan for managing PHI/PII data. This effort remains anticipated to commence in February, after Release 3.12 is completed. IV&V will continue to monitor this finding. 12/31/2020 - BHA is still in the process of establishing a plan for managing PHI/PII data and plans to complete this effort in February after Release 3.12. IV&V will continue to monitor this finding.					
			production environments increases the potential for theft, loss or exposure thus increasing the organization's risk. Failure to secure PII/PHI data leaves the organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client	client trust and loyalty.	masking of data. IV&V recommends that DOH mitigates this finding by removing and/or masking any PHI/PII data in its non-production environments. NEW - IV&V recommends DOH consider limiting the volume of environments and access necessary to support development	important security activity will be completed. 01/31/2021 - No substantive changes were observed in January. BHA is still in the process of establishing a plan for managing PHI/PII data. This effort remains anticipated to commence in February, after Release 3.12 is completed. IV&V will continue to monitor this finding. 12/31/2020 - BHA is still in the process of establishing a plan for managing PHI/PII data and plans to complete this effort in February after Release 3.12. IV&V will continue to monitor this finding. 11/30/2020 - DOH is still in the process of					
			production environments increases the potential for theft, loss or exposure thus increasing the organization's risk. Failure to secure PII/PHI data leaves the organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client	client trust and loyalty.	masking of data. IV&V recommends that DOH mitigates this finding by removing and/or masking any PHI/PII data in its non-production environments. NEW - IV&V recommends DOH consider limiting the volume of environments and access necessary to support development	important security activity will be completed. 01/31/2021 - No substantive changes were observed in January. BHA is still in the process of establishing a plan for managing PHI/PII data. This effort remains anticipated to commence in February, after Release 3.12 is completed. IV&V will continue to monitor this finding. 12/31/2020 - BHA is still in the process of establishing a plan for managing PHI/PII data and plans to complete this effort in February after Release 3.12. IV&V will continue to monitor this finding. 11/30/2020 - DOH is still in the process of establishing a plan for managing PHI/PII data					
			production environments increases the potential for theft, loss or exposure thus increasing the organization's risk. Failure to secure PII/PHI data leaves the organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client	client trust and loyalty.	masking of data. IV&V recommends that DOH mitigates this finding by removing and/or masking any PHI/PII data in its non-production environments. NEW - IV&V recommends DOH consider limiting the volume of environments and access necessary to support development	important security activity will be completed. 01/31/2021 - No substantive changes were observed in January. BHA is still in the process of establishing a plan for managing PHI/PII data. This effort remains anticipated to commence in February, after Release 3.12 is completed. IV&V will continue to monitor this finding. 12/31/2020 - BHA is still in the process of establishing a plan for managing PHI/PII data and plans to complete this effort in February after Release 3.12. IV&V will continue to monitor this finding. 11/30/2020 - DOH is still in the process of establishing a plan for managing PHI/PII data and plans to complete this effort in December.					
			production environments increases the potential for theft, loss or exposure thus increasing the organization's risk. Failure to secure PII/PHI data leaves the organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client	client trust and loyalty.	masking of data. IV&V recommends that DOH mitigates this finding by removing and/or masking any PHI/PII data in its non-production environments. NEW - IV&V recommends DOH consider limiting the volume of environments and access necessary to support development	important security activity will be completed. 01/31/2021 - No substantive changes were observed in January. BHA is still in the process of establishing a plan for managing PHI/PII data. This effort remains anticipated to commence in February, after Release 3.12 is completed. IV&V will continue to monitor this finding. 12/31/2020 - BHA is still in the process of establishing a plan for managing PHI/PII data and plans to complete this effort in February after Release 3.12. IV&V will continue to monitor this finding. 11/30/2020 - DOH is still in the process of establishing a plan for managing PHI/PII data and plans to complete this effort in December. Due to the security nature of PHI/PII data, IV&V					
			production environments increases the potential for theft, loss or exposure thus increasing the organization's risk. Failure to secure PII/PHI data leaves the organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client	client trust and loyalty.	masking of data. IV&V recommends that DOH mitigates this finding by removing and/or masking any PHI/PII data in its non-production environments. NEW - IV&V recommends DOH consider limiting the volume of environments and access necessary to support development	important security activity will be completed. 01/31/2021 - No substantive changes were observed in January. BHA is still in the process of establishing a plan for managing PHI/PII data. This effort remains anticipated to commence in February, after Release 3.12 is completed. IV&V will continue to monitor this finding. 12/31/2020 - BHA is still in the process of establishing a plan for managing PHI/PII data and plans to complete this effort in February after Release 3.12. IV&V will continue to monitor this finding. 11/30/2020 - DOH is still in the process of establishing a plan for managing PHI/PII data and plans to complete this effort in December. Due to the security nature of PHI/PII data, IV&V has escalated this finding from a preliminary					
			production environments increases the potential for theft, loss or exposure thus increasing the organization's risk. Failure to secure PII/PHI data leaves the organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client	client trust and loyalty.	masking of data. IV&V recommends that DOH mitigates this finding by removing and/or masking any PHI/PII data in its non-production environments. NEW - IV&V recommends DOH consider limiting the volume of environments and access necessary to support development	important security activity will be completed. 01/31/2021 - No substantive changes were observed in January. BHA is still in the process of establishing a plan for managing PHI/PII data. This effort remains anticipated to commence in February, after Release 3.12 is completed. IV&V will continue to monitor this finding. 12/31/2020 - BHA is still in the process of establishing a plan for managing PHI/PII data and plans to complete this effort in February after Release 3.12. IV&V will continue to monitor this finding. 11/30/2020 - DOH is still in the process of establishing a plan for managing PHI/PII data and plans to complete this effort in December. Due to the security nature of PHI/PII data, IV&V has escalated this finding from a preliminary concern to a low priority risk and will continue					

14.000	8/31/2020	Project not able to access Activity Logs	The Project recently deployed audit	The unavailability of activity	IV&V recommends that DHS continues to	02/28/2021 - BHA continued this effort in	Release/Deployment	Risk	Low	Open	D
2000	0,52,2020	l reject not able to access richticy logs	log functionality into production	logs may hamper the	collaborate with Microsoft until the	' '	Planning			l l	Macdonald
			whereby these logs can be accessed		activity logging feature is available in all	from Microsoft due to a layering issue. Based					, , , , , , , , , , , , , , , , , , ,
			and exported as needed. However,	breaches.	BHA non-production environments.	on continued delays, it is unclear when this					
			IV&V was made aware access to	breaches.	britain production environments.	important security activity will be completed.					
			activity logging for users with just			IV&V will continue to monitor this finding.					
			view permissions will not be			01/31/2021 - The implementation effort for					
			available from Microsoft in the			this activity moved forward in January. Some					
			public sector environment until the			of the entities will have activity logging					
			end of September 2020. The								
			unavailability of these specific			completed in the planned early February Release 3.12, while others will be delayed until					
			activity logs could potentially			Release 3.13. IVV will continue to monitor.					
			hamper the investigation of future			12/31/2020 - The planning effort for identifying					
			security events until implemented.			the entities that will require activation of the					
			security events until implemented.			•					
						new activity logs was completed during December. The implementation effort has been					
						prioritized for inclusion in Release 3.12. IV&V					
						will continue to monitor this finding until					
						implemented. 11/30/2020 - The DOH technical team has					
						commenced the analytical effort to determine					
						· ·					
						which entities to activate the logging features for, as well as which entities will not require					
						this action. IV&V will continue to monitor this					
						finding until successfully implemented.					
						10/31/2020 - Microsoft's implementation of					
						the entional components of the logging					
45.000	0/20/2020	2 December 1 de la constitución	Contains defeate identified in Assesse	The interest first and accept to the contract	To add an annual to insure the Dunion	the optional components of the logging	Duringt Management	l	LU -la	0	
15.000	9/30/2020	Due to multiple quality concerns, the	System defects identified in August	The identified quality issues	To address quality issues, the Project	02/28/2021 - R3.12 was promoted to	Project Management	Issue	High	Open	D
15.000	9/30/2020	project may continue to face impactful	that affected claims were due to	have negatively affected DOH	should continue to pursue and/or	02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately	Project Management	Issue	High	Open	D Macdonald
15.000	9/30/2020	1	that affected claims were due to multi-faceted quality issues were	have negatively affected DOH billing processes and DOH has	should continue to pursue and/or consider:	02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release.	Project Management	Issue	High	Open	D Macdonald
15.000	9/30/2020	project may continue to face impactful	that affected claims were due to multi-faceted quality issues were individually addressed during this	have negatively affected DOH billing processes and DOH has stated these are the most	should continue to pursue and/or consider: 1) Perform revenue neutrality fiscal	02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD	Project Management	Issue	High	Open	D Macdonald
15.000	9/30/2020	project may continue to face impactful	that affected claims were due to multi-faceted quality issues were individually addressed during this reporting period. IV&V notes that	have negatively affected DOH billing processes and DOH has stated these are the most impactful defects discovered to	should continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to	02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress	Project Management	Issue	High	Open	D Macdonald
15.000	9/30/2020	project may continue to face impactful	that affected claims were due to multi-faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still	have negatively affected DOH billing processes and DOH has stated these are the most	should continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected.	02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on	Project Management	Issue	High	Open	D Macdonald
15.000	9/30/2020	project may continue to face impactful	that affected claims were due to multi-faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a	have negatively affected DOH billing processes and DOH has stated these are the most impactful defects discovered to	should continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing	02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021.	Project Management	Issue	High	Open	D Macdonald
15.000	9/30/2020	project may continue to face impactful	that affected claims were due to multi-faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall,	have negatively affected DOH billing processes and DOH has stated these are the most impactful defects discovered to	should continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User	02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021. BHA initiated an RCA for the R3.12 defects to	Project Management	Issue	High	Open	D Macdonald
15.000	9/30/2020	project may continue to face impactful	that affected claims were due to multi-faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded	have negatively affected DOH billing processes and DOH has stated these are the most impactful defects discovered to	should continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression	02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021. BHA initiated an RCA for the R3.12 defects to help with quality improvement and to ensure	Project Management	Issue	High	Open	D Macdonald
15.000	9/30/2020	project may continue to face impactful	that affected claims were due to multi-faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase	have negatively affected DOH billing processes and DOH has stated these are the most impactful defects discovered to	should continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing.	02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021. BHA initiated an RCA for the R3.12 defects to help with quality improvement and to ensure these same issues do not recur in future	Project Management	Issue	High	Open	D Macdonald
15.000	9/30/2020	project may continue to face impactful	that affected claims were due to multi-faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process	have negatively affected DOH billing processes and DOH has stated these are the most impactful defects discovered to	should continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 3) Assigning a dedicated resource to	02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021. BHA initiated an RCA for the R3.12 defects to help with quality improvement and to ensure these same issues do not recur in future releases. Completion of the RCA is expected in	Project Management	Issue	High	Open	D Macdonald
15.000	9/30/2020	project may continue to face impactful	that affected claims were due to multi-faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to	have negatively affected DOH billing processes and DOH has stated these are the most impactful defects discovered to	should continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 3) Assigning a dedicated resource to provide oversight of CAMHD Fiscal	02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021. BHA initiated an RCA for the R3.12 defects to help with quality improvement and to ensure these same issues do not recur in future releases. Completion of the RCA is expected in early March.	Project Management	Issue	High	Open	D Macdonald
15.000	9/30/2020	project may continue to face impactful	that affected claims were due to multi-faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These	have negatively affected DOH billing processes and DOH has stated these are the most impactful defects discovered to	should continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 3) Assigning a dedicated resource to provide oversight of CAMHD Fiscal Processes.	02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021. BHA initiated an RCA for the R3.12 defects to help with quality improvement and to ensure these same issues do not recur in future releases. Completion of the RCA is expected in early March. IV&V notes that DOH is working with Microsoft	Project Management	Issue	High	Open	D Macdonald
15.000	9/30/2020	project may continue to face impactful	that affected claims were due to multi-faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently include:	have negatively affected DOH billing processes and DOH has stated these are the most impactful defects discovered to	should continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 3) Assigning a dedicated resource to provide oversight of CAMHD Fiscal Processes. 4) BHA and RSM to collaborate on the	02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021. BHA initiated an RCA for the R3.12 defects to help with quality improvement and to ensure these same issues do not recur in future releases. Completion of the RCA is expected in early March. IV&V notes that DOH is working with Microsoft to schedule time in March/April to commence	Project Management	Issue	High	Open	D Macdonald
15.000	9/30/2020	project may continue to face impactful	that affected claims were due to multi-faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently include:	have negatively affected DOH billing processes and DOH has stated these are the most impactful defects discovered to date.	should continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 3) Assigning a dedicated resource to provide oversight of CAMHD Fiscal Processes. 4) BHA and RSM to collaborate on the necessary revisions to the submitted	02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021. BHA initiated an RCA for the R3.12 defects to help with quality improvement and to ensure these same issues do not recur in future releases. Completion of the RCA is expected in early March. IV&V notes that DOH is working with Microsoft to schedule time in March/April to commence the efforts for regression testing automation.	Project Management	Issue	High	Open	D Macdonald
15.000	9/30/2020	project may continue to face impactful	that affected claims were due to multi-faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue	have negatively affected DOH billing processes and DOH has stated these are the most impactful defects discovered to date.	should continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 3) Assigning a dedicated resource to provide oversight of CAMHD Fiscal Processes. 4) BHA and RSM to collaborate on the necessary revisions to the submitted design deliverables to increase level of	02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021. BHA initiated an RCA for the R3.12 defects to help with quality improvement and to ensure these same issues do not recur in future releases. Completion of the RCA is expected in early March. IV&V notes that DOH is working with Microsoft to schedule time in March/April to commence the efforts for regression testing automation. This functionality is expected to provide	Project Management	Issue	High	Open	D Macdonald
15.000	9/30/2020	project may continue to face impactful	that affected claims were due to multi-faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from	have negatively affected DOH billing processes and DOH has stated these are the most impactful defects discovered to date.	should continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 3) Assigning a dedicated resource to provide oversight of CAMHD Fiscal Processes. 4) BHA and RSM to collaborate on the necessary revisions to the submitted design deliverables to increase level of detail and quality - Completed	02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021. BHA initiated an RCA for the R3.12 defects to help with quality improvement and to ensure these same issues do not recur in future releases. Completion of the RCA is expected in early March. IV&V notes that DOH is working with Microsoft to schedule time in March/April to commence the efforts for regression testing automation. This functionality is expected to provide repeatable, automated regression test efforts	Project Management	Issue	High	Open	D Macdonald
15.000	9/30/2020	project may continue to face impactful	that affected claims were due to multi-faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next.	have negatively affected DOH billing processes and DOH has stated these are the most impactful defects discovered to date.	should continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 3) Assigning a dedicated resource to provide oversight of CAMHD Fiscal Processes. 4) BHA and RSM to collaborate on the necessary revisions to the submitted design deliverables to increase level of detail and quality - Completed 5) Monitor implemented improvements	02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021. BHA initiated an RCA for the R3.12 defects to help with quality improvement and to ensure these same issues do not recur in future releases. Completion of the RCA is expected in early March. IV&V notes that DOH is working with Microsoft to schedule time in March/April to commence the efforts for regression testing automation. This functionality is expected to provide repeatable, automated regression test efforts for CAMHD and DDD in downstream releases.	Project Management	Issue	High	Open	D Macdonald
15.000	9/30/2020	project may continue to face impactful	that affected claims were due to multi-faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting System Integration	have negatively affected DOH billing processes and DOH has stated these are the most impactful defects discovered to date.	should continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 3) Assigning a dedicated resource to provide oversight of CAMHD Fiscal Processes. 4) BHA and RSM to collaborate on the necessary revisions to the submitted design deliverables to increase level of detail and quality - Completed 5) Monitor implemented improvements for effectiveness In Progress	02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021. BHA initiated an RCA for the R3.12 defects to help with quality improvement and to ensure these same issues do not recur in future releases. Completion of the RCA is expected in early March. IV&V notes that DOH is working with Microsoft to schedule time in March/April to commence the efforts for regression testing automation. This functionality is expected to provide repeatable, automated regression test efforts for CAMHD and DDD in downstream releases. DOH is working to identify both internal DOH	Project Management	Issue	High	Open	D Macdonald
15.000	9/30/2020	project may continue to face impactful	that affected claims were due to multi-faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting System Integration Testing, User Acceptance Testing,	have negatively affected DOH billing processes and DOH has stated these are the most impactful defects discovered to date.	should continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 3) Assigning a dedicated resource to provide oversight of CAMHD Fiscal Processes. 4) BHA and RSM to collaborate on the necessary revisions to the submitted design deliverables to increase level of detail and quality - Completed 5) Monitor implemented improvements for effectiveness In Progress 6) Evaluate existing project staff skills and	02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021. BHA initiated an RCA for the R3.12 defects to help with quality improvement and to ensure these same issues do not recur in future releases. Completion of the RCA is expected in early March. IV&V notes that DOH is working with Microsoft to schedule time in March/April to commence the efforts for regression testing automation. This functionality is expected to provide repeatable, automated regression test efforts for CAMHD and DDD in downstream releases. DOH is working to identify both internal DOH and external Microsoft resource participants	Project Management	Issue	High	Open	D Macdonald
15.000	9/30/2020	project may continue to face impactful	that affected claims were due to multi-faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting System Integration Testing, User Acceptance Testing, Performance Testing, and	have negatively affected DOH billing processes and DOH has stated these are the most impactful defects discovered to date.	should continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 3) Assigning a dedicated resource to provide oversight of CAMHD Fiscal Processes. 4) BHA and RSM to collaborate on the necessary revisions to the submitted design deliverables to increase level of detail and quality - Completed 5) Monitor implemented improvements for effectiveness In Progress 6) Evaluate existing project staff skills and experience level to ensure they meet BHA	02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021. BHA initiated an RCA for the R3.12 defects to help with quality improvement and to ensure these same issues do not recur in future releases. Completion of the RCA is expected in early March. IV&V notes that DOH is working with Microsoft to schedule time in March/April to commence the efforts for regression testing automation. This functionality is expected to provide repeatable, automated regression test efforts for CAMHD and DDD in downstream releases. DOH is working to identify both internal DOH and external Microsoft resource participants for this effort.	Project Management	Issue	High	Open	D Macdonald
15.000	9/30/2020	project may continue to face impactful	that affected claims were due to multi-faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting System Integration Testing, User Acceptance Testing, Performance Testing, and Regression Testing for Release 3.10.	have negatively affected DOH billing processes and DOH has stated these are the most impactful defects discovered to date.	should continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 3) Assigning a dedicated resource to provide oversight of CAMHD Fiscal Processes. 4) BHA and RSM to collaborate on the necessary revisions to the submitted design deliverables to increase level of detail and quality - Completed 5) Monitor implemented improvements for effectiveness In Progress 6) Evaluate existing project staff skills and experience level to ensure they meet BHA support requirements - Open	02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021. BHA initiated an RCA for the R3.12 defects to help with quality improvement and to ensure these same issues do not recur in future releases. Completion of the RCA is expected in early March. IV&V notes that DOH is working with Microsoft to schedule time in March/April to commence the efforts for regression testing automation. This functionality is expected to provide repeatable, automated regression test efforts for CAMHD and DDD in downstream releases. DOH is working to identify both internal DOH and external Microsoft resource participants for this effort. 01/31/2021 - Quality issues persisted in	Project Management	Issue	High	Open	D Macdonald
15.000	9/30/2020	project may continue to face impactful	that affected claims were due to multi-faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting System Integration Testing, User Acceptance Testing, Performance Testing, and Regression Testing for Release 3.10. IV&V will continue to monitor the	have negatively affected DOH billing processes and DOH has stated these are the most impactful defects discovered to date.	should continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 3) Assigning a dedicated resource to provide oversight of CAMHD Fiscal Processes. 4) BHA and RSM to collaborate on the necessary revisions to the submitted design deliverables to increase level of detail and quality - Completed 5) Monitor implemented improvements for effectiveness In Progress 6) Evaluate existing project staff skills and experience level to ensure they meet BHA support requirements - Open 7) IV&V recommends performing an RCA	02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021. BHA initiated an RCA for the R3.12 defects to help with quality improvement and to ensure these same issues do not recur in future releases. Completion of the RCA is expected in early March. IV&V notes that DOH is working with Microsoft to schedule time in March/April to commence the efforts for regression testing automation. This functionality is expected to provide repeatable, automated regression test efforts for CAMHD and DDD in downstream releases. DOH is working to identify both internal DOH and external Microsoft resource participants for this effort. 01/31/2021 - Quality issues persisted in January as regression testing and deployments	Project Management	Issue	High	Open	D Macdonald
15.000	9/30/2020	project may continue to face impactful	that affected claims were due to multi-faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting System Integration Testing, User Acceptance Testing, Performance Testing, and Regression Testing for Release 3.10. IV&V will continue to monitor the testing efforts throughout the	have negatively affected DOH billing processes and DOH has stated these are the most impactful defects discovered to date.	should continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 3) Assigning a dedicated resource to provide oversight of CAMHD Fiscal Processes. 4) BHA and RSM to collaborate on the necessary revisions to the submitted design deliverables to increase level of detail and quality - Completed 5) Monitor implemented improvements for effectiveness In Progress 6) Evaluate existing project staff skills and experience level to ensure they meet BHA support requirements - Open 7) IV&V recommends performing an RCA in collaboration with RSM after all future	02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021. BHA initiated an RCA for the R3.12 defects to help with quality improvement and to ensure these same issues do not recur in future releases. Completion of the RCA is expected in early March. IV&V notes that DOH is working with Microsoft to schedule time in March/April to commence the efforts for regression testing automation. This functionality is expected to provide repeatable, automated regression test efforts for CAMHD and DDD in downstream releases. DOH is working to identify both internal DOH and external Microsoft resource participants for this effort. 01/31/2021 - Quality issues persisted in January as regression testing and deployments (non-production and production) issues have	Project Management	Issue	High	Open	D Macdonald
15.000	9/30/2020	project may continue to face impactful	that affected claims were due to multi-faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting System Integration Testing, User Acceptance Testing, Performance Testing, and Regression Testing for Release 3.10. IV&V will continue to monitor the testing efforts throughout the balance of Release 3.10 and	have negatively affected DOH billing processes and DOH has stated these are the most impactful defects discovered to date.	should continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 3) Assigning a dedicated resource to provide oversight of CAMHD Fiscal Processes. 4) BHA and RSM to collaborate on the necessary revisions to the submitted design deliverables to increase level of detail and quality - Completed 5) Monitor implemented improvements for effectiveness In Progress 6) Evaluate existing project staff skills and experience level to ensure they meet BHA support requirements - Open 7) IV&V recommends performing an RCA in collaboration with RSM after all future release deployments for continual quality	02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021. BHA initiated an RCA for the R3.12 defects to help with quality improvement and to ensure these same issues do not recur in future releases. Completion of the RCA is expected in early March. IV&V notes that DOH is working with Microsoft to schedule time in March/April to commence the efforts for regression testing automation. This functionality is expected to provide repeatable, automated regression test efforts for CAMHD and DDD in downstream releases. DOH is working to identify both internal DOH and external Microsoft resource participants for this effort. 01/31/2021 - Quality issues persisted in January as regression testing and deployments (non-production and production) issues have impacted the planned DDI activities. Root cause	Project Management	Issue	High	Open	D Macdonald
15.000	9/30/2020	project may continue to face impactful	that affected claims were due to multi-faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting System Integration Testing, User Acceptance Testing, Performance Testing, and Regression Testing for Release 3.10. IV&V will continue to monitor the testing efforts throughout the	have negatively affected DOH billing processes and DOH has stated these are the most impactful defects discovered to date.	should continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 3) Assigning a dedicated resource to provide oversight of CAMHD Fiscal Processes. 4) BHA and RSM to collaborate on the necessary revisions to the submitted design deliverables to increase level of detail and quality - Completed 5) Monitor implemented improvements for effectiveness In Progress 6) Evaluate existing project staff skills and experience level to ensure they meet BHA support requirements - Open 7) IV&V recommends performing an RCA in collaboration with RSM after all future	02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021. BHA initiated an RCA for the R3.12 defects to help with quality improvement and to ensure these same issues do not recur in future releases. Completion of the RCA is expected in early March. IV&V notes that DOH is working with Microsoft to schedule time in March/April to commence the efforts for regression testing automation. This functionality is expected to provide repeatable, automated regression test efforts for CAMHD and DDD in downstream releases. DOH is working to identify both internal DOH and external Microsoft resource participants for this effort. 01/31/2021 - Quality issues persisted in January as regression testing and deployments (non-production and production) issues have	Project Management	Issue	High	Open	D Macdonald

16.000	10/5/2020	Usage of Semantics and IDM for	The project noted its intent to			01/31/2021 - The project has made great	Targeted KT	Concern		Closed	The project	D
16.000	10/5/2020	development and ongoing	obtain more targeted knowledge			strides addressing this concern. A Semantics	Targeted KT	Concern				Macdonald
		maintenance of the system requires	transfer of both the Semantics			Layer KT session was conducted on 1/29/21					good	iviacuonalu
		BHA to take a proactive approach to	Reporting and IDM tools. IV&V will			and multiple IDM and Semantic Layer sessions					progress	
		support of these tools.	continue to monitor this concern.			has been scheduled in February. IV&V is closing					establishing	
		support of these tools.	Continue to monitor this concern.			this finding as we no longer view this item as a					and initial	
						concern.					execution of	
						12/31/2020 - IV&V is aware that an overview of					the IDM and	
						the Semantics Layer KT session was held on					Semantics	
						12/16/20. The planning effort will result in					Layer KT	
						additional Semantic Layer and IDM KT sessions					plan.	
						in the coming months. IV&V will continue to					pian.	
						monitor this finding.						
						11/30/2020 - The project conducted two high-						
						level overview sessions of the Semantic Layer						
						Reporting tools during November. One session						
						was focused on the overall Semantic Layer, and						
						the second session was focused on Semantic						
						Layer Security. Additional targeted Knowledge						
						Transfer sessions on the Semantic Layer tools						
						will need to be provided by RSM; however,						
						these have not been scheduled. IV&V will						
						continue to monitor this finding.						
						10/31/2020 - The project intends to obtain						
						more targeted knowledge transfer for both the						
						Semantics Reporting and IDM tools and will be						
						planning and scheduling these sessions with						
						pianning and scheduling these sessions with						
17.000	10/27/2020	The bandwidth of CAMHD Leadership	CAMHD has been provided with an	CAMDH Leadership	IV&V recommends CAMHD look for	, ,	Project Management	Risk	Low	Open		D
17.000	10/27/2020	The bandwidth of CAMHD Leadership is being hampered by planning tasks	CAMHD has been provided with an approval to commence planning	CAMDH Leadership participation in key activities	IV&V recommends CAMHD look for opportunities to augment the	, ,	Project Management	Risk	Low	Open		D Macdonald
17.000	10/27/2020		'	participation in key activities		02/28/2021 - CAMHD Leadership continued to	Project Management	Risk	Low	Open		_
17.000	10/27/2020	is being hampered by planning tasks	approval to commence planning	participation in key activities	opportunities to augment the	02/28/2021 - CAMHD Leadership continued to spend upwards of 1/3 of available time in the	Project Management	Risk	Low	Open		_
17.000	10/27/2020	is being hampered by planning tasks and activities for assessing project	approval to commence planning efforts for expansion of the project	participation in key activities could be significantly hindered	opportunities to augment the management staffing for planning Phase 4	02/28/2021 - CAMHD Leadership continued to spend upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which	Project Management	Risk	Low	Open		_
17.000	10/27/2020	is being hampered by planning tasks and activities for assessing project	approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH.	participation in key activities could be significantly hindered by the flood of activities that	opportunities to augment the management staffing for planning Phase 4	02/28/2021 - CAMHD Leadership continued to spend upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the	Project Management	Risk	Low	Open		_
17.000	10/27/2020	is being hampered by planning tasks and activities for assessing project	approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently	participation in key activities could be significantly hindered by the flood of activities that could occur as the department	opportunities to augment the management staffing for planning Phase 4	02/28/2021 - CAMHD Leadership continued to spend upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of	Project Management	Risk	Low	Open		_
17.000	10/27/2020	is being hampered by planning tasks and activities for assessing project	approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time	participation in key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this	opportunities to augment the management staffing for planning Phase 4	02/28/2021 - CAMHD Leadership continued to spend upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of dedication to this effort is certain to continue	Project Management	Risk	Low	Open		_
17.000	10/27/2020	is being hampered by planning tasks and activities for assessing project	approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time	participation in key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project to the balance of	opportunities to augment the management staffing for planning Phase 4	02/28/2021 - CAMHD Leadership continued to spend upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of dedication to this effort is certain to continue to increase in the coming months. IV&V will	Project Management	Risk	Low	Open		_
17.000	10/27/2020	is being hampered by planning tasks and activities for assessing project	approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time	participation in key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project to the balance of	opportunities to augment the management staffing for planning Phase 4	02/28/2021 - CAMHD Leadership continued to spend upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of dedication to this effort is certain to continue to increase in the coming months. IV&V will continue to monitor this finding. 01/31/2021 - The CAMHD Leadership is now spending upwards of 1/3 of available time in	Project Management	Risk	Low	Open		_
17.000	10/27/2020	is being hampered by planning tasks and activities for assessing project	approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time	participation in key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project to the balance of	opportunities to augment the management staffing for planning Phase 4	02/28/2021 - CAMHD Leadership continued to spend upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of dedication to this effort is certain to continue to increase in the coming months. IV&V will continue to monitor this finding. 01/31/2021 - The CAMHD Leadership is now spending upwards of 1/3 of available time in the planning effort for Phase 4 of the Project,	Project Management	Risk	Low	Open		_
17.000	10/27/2020	is being hampered by planning tasks and activities for assessing project	approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time	participation in key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project to the balance of	opportunities to augment the management staffing for planning Phase 4	02/28/2021 - CAMHD Leadership continued to spend upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of dedication to this effort is certain to continue to increase in the coming months. IV&V will continue to monitor this finding. 01/31/2021 - The CAMHD Leadership is now spending upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution	Project Management	Risk	Low	Open		_
17.000	10/27/2020	is being hampered by planning tasks and activities for assessing project	approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time	participation in key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project to the balance of	opportunities to augment the management staffing for planning Phase 4	02/28/2021 - CAMHD Leadership continued to spend upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of dedication to this effort is certain to continue to increase in the coming months. IV&V will continue to monitor this finding. 01/31/2021 - The CAMHD Leadership is now spending upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of	Project Management	Risk	Low	Open		_
17.000	10/27/2020	is being hampered by planning tasks and activities for assessing project	approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time	participation in key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project to the balance of	opportunities to augment the management staffing for planning Phase 4	02/28/2021 - CAMHD Leadership continued to spend upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of dedication to this effort is certain to continue to increase in the coming months. IV&V will continue to monitor this finding. 01/31/2021 - The CAMHD Leadership is now spending upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of dedication to this effort is certain to continue	Project Management	Risk	Low	Open		_
17.000	10/27/2020	is being hampered by planning tasks and activities for assessing project	approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time	participation in key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project to the balance of	opportunities to augment the management staffing for planning Phase 4	02/28/2021 - CAMHD Leadership continued to spend upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of dedication to this effort is certain to continue to increase in the coming months. IV&V will continue to monitor this finding. 01/31/2021 - The CAMHD Leadership is now spending upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of dedication to this effort is certain to continue to increase in the coming months.	Project Management	Risk	Low	Open		_
17.000	10/27/2020	is being hampered by planning tasks and activities for assessing project	approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time	participation in key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project to the balance of	opportunities to augment the management staffing for planning Phase 4	02/28/2021 - CAMHD Leadership continued to spend upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of dedication to this effort is certain to continue to increase in the coming months. IV&V will continue to monitor this finding. 01/31/2021 - The CAMHD Leadership is now spending upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of dedication to this effort is certain to continue to increase in the coming months. 12/31/2020 - The planning effort for the	Project Management	Risk	Low	Open		_
17.000	10/27/2020	is being hampered by planning tasks and activities for assessing project	approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time	participation in key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project to the balance of	opportunities to augment the management staffing for planning Phase 4	02/28/2021 - CAMHD Leadership continued to spend upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of dedication to this effort is certain to continue to increase in the coming months. IV&V will continue to monitor this finding. 01/31/2021 - The CAMHD Leadership is now spending upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of dedication to this effort is certain to continue to increase in the coming months. 12/31/2020 - The planning effort for the expansion of the case management solution to	Project Management	Risk	Low	Open		_
17.000	10/27/2020	is being hampered by planning tasks and activities for assessing project	approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time	participation in key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project to the balance of	opportunities to augment the management staffing for planning Phase 4	02/28/2021 - CAMHD Leadership continued to spend upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of dedication to this effort is certain to continue to increase in the coming months. IV&V will continue to monitor this finding. 01/31/2021 - The CAMHD Leadership is now spending upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of dedication to this effort is certain to continue to increase in the coming months. 12/31/2020 - The planning effort for the expansion of the case management solution to the other DOH divisions continued during	Project Management	Risk	Low	Open		_
17.000	10/27/2020	is being hampered by planning tasks and activities for assessing project	approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time	participation in key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project to the balance of	opportunities to augment the management staffing for planning Phase 4	02/28/2021 - CAMHD Leadership continued to spend upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of dedication to this effort is certain to continue to increase in the coming months. IV&V will continue to monitor this finding. 01/31/2021 - The CAMHD Leadership is now spending upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of dedication to this effort is certain to continue to increase in the coming months. 12/31/2020 - The planning effort for the expansion of the case management solution to the other DOH divisions continued during December. CAMHD Leadership continues to	Project Management	Risk	Low	Open		_
17.000	10/27/2020	is being hampered by planning tasks and activities for assessing project	approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time	participation in key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project to the balance of	opportunities to augment the management staffing for planning Phase 4	02/28/2021 - CAMHD Leadership continued to spend upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of dedication to this effort is certain to continue to increase in the coming months. IV&V will continue to monitor this finding. 01/31/2021 - The CAMHD Leadership is now spending upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of dedication to this effort is certain to continue to increase in the coming months. 12/31/2020 - The planning effort for the expansion of the case management solution to the other DOH divisions continued during December. CAMHD Leadership continues to dedicate approximately 25% of available time	Project Management	Risk	Low	Open		_
17.000	10/27/2020	is being hampered by planning tasks and activities for assessing project	approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time	participation in key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project to the balance of	opportunities to augment the management staffing for planning Phase 4	02/28/2021 - CAMHD Leadership continued to spend upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of dedication to this effort is certain to continue to increase in the coming months. IV&V will continue to monitor this finding. 01/31/2021 - The CAMHD Leadership is now spending upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of dedication to this effort is certain to continue to increase in the coming months. 12/31/2020 - The planning effort for the expansion of the case management solution to the other DOH divisions continued during December. CAMHD Leadership continues to dedicate approximately 25% of available time to this planning effort and it is anticipated that	Project Management	Risk	Low	Open		_
17.000	10/27/2020	is being hampered by planning tasks and activities for assessing project	approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time	participation in key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project to the balance of	opportunities to augment the management staffing for planning Phase 4	02/28/2021 - CAMHD Leadership continued to spend upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of dedication to this effort is certain to continue to increase in the coming months. IV&V will continue to monitor this finding. 01/31/2021 - The CAMHD Leadership is now spending upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of dedication to this effort is certain to continue to increase in the coming months. 12/31/2020 - The planning effort for the expansion of the case management solution to the other DOH divisions continued during December. CAMHD Leadership continues to dedicate approximately 25% of available time to this planning effort and it is anticipated that the level of effort will continue to increase in	Project Management	Risk	Low	Open		_
17.000	10/27/2020	is being hampered by planning tasks and activities for assessing project	approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time	participation in key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project to the balance of	opportunities to augment the management staffing for planning Phase 4	02/28/2021 - CAMHD Leadership continued to spend upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of dedication to this effort is certain to continue to increase in the coming months. IV&V will continue to monitor this finding. 01/31/2021 - The CAMHD Leadership is now spending upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of dedication to this effort is certain to continue to increase in the coming months. 12/31/2020 - The planning effort for the expansion of the case management solution to the other DOH divisions continued during December. CAMHD Leadership continues to dedicate approximately 25% of available time to this planning effort and it is anticipated that the level of effort will continue to increase in the coming months. On the positive side,	Project Management	Risk	Low	Open		_
17.000	10/27/2020	is being hampered by planning tasks and activities for assessing project	approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time	participation in key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project to the balance of	opportunities to augment the management staffing for planning Phase 4	02/28/2021 - CAMHD Leadership continued to spend upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of dedication to this effort is certain to continue to increase in the coming months. IV&V will continue to monitor this finding. 01/31/2021 - The CAMHD Leadership is now spending upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of dedication to this effort is certain to continue to increase in the coming months. 12/31/2020 - The planning effort for the expansion of the case management solution to the other DOH divisions continued during December. CAMHD Leadership continues to dedicate approximately 25% of available time to this planning effort and it is anticipated that the level of effort will continue to increase in the coming months. On the positive side, CAMHD leadership time dedicated to the	Project Management	Risk	Low	Open		_
17.000	10/27/2020	is being hampered by planning tasks and activities for assessing project	approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time	participation in key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project to the balance of	opportunities to augment the management staffing for planning Phase 4	02/28/2021 - CAMHD Leadership continued to spend upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of dedication to this effort is certain to continue to increase in the coming months. IV&V will continue to monitor this finding. 01/31/2021 - The CAMHD Leadership is now spending upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of dedication to this effort is certain to continue to increase in the coming months. 12/31/2020 - The planning effort for the expansion of the case management solution to the other DOH divisions continued during December. CAMHD Leadership continues to dedicate approximately 25% of available time to this planning effort and it is anticipated that the level of effort will continue to increase in the coming months. On the positive side, CAMHD leadership time dedicated to the COVID response decreased during December.	Project Management	Risk	Low	Open		_
17.000	10/27/2020	is being hampered by planning tasks and activities for assessing project	approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time	participation in key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project to the balance of	opportunities to augment the management staffing for planning Phase 4	02/28/2021 - CAMHD Leadership continued to spend upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of dedication to this effort is certain to continue to increase in the coming months. IV&V will continue to monitor this finding. 01/31/2021 - The CAMHD Leadership is now spending upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of dedication to this effort is certain to continue to increase in the coming months. 12/31/2020 - The planning effort for the expansion of the case management solution to the other DOH divisions continued during December. CAMHD Leadership continues to dedicate approximately 25% of available time to this planning effort and it is anticipated that the level of effort will continue to increase in the coming months. On the positive side, CAMHD leadership time dedicated to the	Project Management	Risk	Low	Open		_

18.000	11/20/2022	Due to consistent to desired to a	The IDM and Comments I - I CC .		11/10 \ / management and a the construct to the construction	02/20/2021 DUA	Dalagas/Davilerman	Issue	Litterla	0		
18.000	11/30/2020	Due to consistent technical issues	The IDM and Semantic layer efforts		IV&V recommends the project to continue	02/28/2021 - BHA continues to work with	Release/Deployment	Issue	High	Open	Macdo	امامماما
		requiring escalation to Microsoft,	have experienced several delays		to monitor the status of outstanding	Microsoft on technical issues as they arise in	Planning				IVIACUO	ionaid
		some project efforts are being delayed.	attributable to issues escalated to Microsoft. The issues have ranged		Microsoft tickets and to escalate the	the Government Community Cloud (GCC) instance. IV&V will continue to monitor this						
		delayed.	from administrative /		priority of these tickets as deemed	finding.						
			communication (entering issues		necessary.	01/31/2020 - While most of the Microsoft						
			into the Commercial support			issues were fixed, the 'first 10 rows', the 'multi-						
			instance vs the Government Cloud			select options', and 'unmanaged layer on the						
			support instance), to several key			Case entity' issues are partially outstanding						
			technical issues requiring assistance									
			to resolve. To date, these support			impacting project timelines. As temporary measures, the project has developed						
			needs have added over a month to			workarounds. Per BHA, the Product Roadmap						
			the IDM and Semantic Layer project			for the GCC product continues to lag behind						
			schedules.			commercial instances which causes						
			Schedules.			uncertainties for the BHA-ITS Project. BHA						
						plans to meet with senior Microsoft						
						management to discuss during February. IV&V						
						will continue to monitor.						
						12/31/2020 - While most of the issues						
						requiring escalation to Microsoft were						
						adequately addressed during December, the						
						Azure Data Factory (ADF) 'first 10 rows missing						
						data' issue remain open. BHA has created a						
						work around for this issue while awaiting a						
						permanent and reliable resolution from						
						Microsoft. Additionally, the Project awaits the						
						"Datalake" function fix from Microsoft to						
19.000	12/31/2020	Due to on-going deployment	There have been several defects	Repeatable documented	Develop a plan to institutionalize the	02/28/2021 - R3.12 was promoted to	Release/Deployment	Issue	High	Open	D	
19.000	12/31/2020	Due to on-going deployment processes and technical execution	There have been several defects pushed to production with Phase 3	Repeatable documented release and deployment will	Develop a plan to institutionalize the execution of "Smoke Testing" for		Release/Deployment Planning	Issue	High	Open	D Macdo	donald
19.000	12/31/2020			'		02/28/2021 - R3.12 was promoted to		Issue	High	Open	D Macdo	donald
19.000	12/31/2020	processes and technical execution	pushed to production with Phase 3 releases. Some of the defects	release and deployment will help ensure that mistakes are	execution of "Smoke Testing" for	02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately		Issue	High	Open	D Macdo	donald
19.000	12/31/2020	processes and technical execution issues, the project may continue to	pushed to production with Phase 3 releases. Some of the defects	release and deployment will help ensure that mistakes are	execution of "Smoke Testing" for promotions to non-production and	02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release.		Issue	High	Open	D Macdo	donald
19.000	12/31/2020	processes and technical execution issues, the project may continue to encounter defects and challenges in meeting projected timelines for production and non-production	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these	release and deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments	execution of "Smoke Testing" for promotions to non-production and production environments. This will help to	02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on		Issue	High	Open	D Macdo	donald
19.000	12/31/2020	processes and technical execution issues, the project may continue to encounter defects and challenges in meeting projected timelines for	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST	release and deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place.	execution of "Smoke Testing" for promotions to non-production and production environments. This will help to ensure that all components needed to test have been properly deployed prior to the actual execution of test activities.	02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021.		Issue	High	Open	D Macdo	donald
19.000	12/31/2020	processes and technical execution issues, the project may continue to encounter defects and challenges in meeting projected timelines for production and non-production	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with	release and deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place.	execution of "Smoke Testing" for promotions to non-production and production environments. This will help to ensure that all components needed to test have been properly deployed prior to the actual execution of test activities. Work in collaboration with RSM to	02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021. BHA initiated an RCA for the R3.12 defects to		Issue	High	Open	D Macdo	donald
19.000	12/31/2020	processes and technical execution issues, the project may continue to encounter defects and challenges in meeting projected timelines for production and non-production	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment	release and deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place.	execution of "Smoke Testing" for promotions to non-production and production environments. This will help to ensure that all components needed to test have been properly deployed prior to the actual execution of test activities. Work in collaboration with RSM to establish a plan for DOH to assume all	02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021. BHA initiated an RCA for the R3.12 defects to help with quality improvement and to ensure		Issue	High	Open	D Macdo	donald
19.000	12/31/2020	processes and technical execution issues, the project may continue to encounter defects and challenges in meeting projected timelines for production and non-production	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing	release and deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place.	execution of "Smoke Testing" for promotions to non-production and production environments. This will help to ensure that all components needed to test have been properly deployed prior to the actual execution of test activities. Work in collaboration with RSM to establish a plan for DOH to assume all deployment activities to ensure complete	02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021. BHA initiated an RCA for the R3.12 defects to help with quality improvement and to ensure these same issues do not recur in future		Issue	High	Open	D Macdo	donald
19.000	12/31/2020	processes and technical execution issues, the project may continue to encounter defects and challenges in meeting projected timelines for production and non-production	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing	release and deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place.	execution of "Smoke Testing" for promotions to non-production and production environments. This will help to ensure that all components needed to test have been properly deployed prior to the actual execution of test activities. Work in collaboration with RSM to establish a plan for DOH to assume all deployment activities to ensure complete ownership of these processes. This should	02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021. BHA initiated an RCA for the R3.12 defects to help with quality improvement and to ensure these same issues do not recur in future releases. Completion of the RCA is expected in		Issue	High	Open	D Macdo	donald
19.000	12/31/2020	processes and technical execution issues, the project may continue to encounter defects and challenges in meeting projected timelines for production and non-production	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware	release and deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place.	execution of "Smoke Testing" for promotions to non-production and production environments. This will help to ensure that all components needed to test have been properly deployed prior to the actual execution of test activities. Work in collaboration with RSM to establish a plan for DOH to assume all deployment activities to ensure complete ownership of these processes. This should assist with consistency in approach and	02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021. BHA initiated an RCA for the R3.12 defects to help with quality improvement and to ensure these same issues do not recur in future releases. Completion of the RCA is expected in early March.		Issue	High	Open	D Macdo	donald
19.000	12/31/2020	processes and technical execution issues, the project may continue to encounter defects and challenges in meeting projected timelines for production and non-production	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff	release and deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place.	execution of "Smoke Testing" for promotions to non-production and production environments. This will help to ensure that all components needed to test have been properly deployed prior to the actual execution of test activities. Work in collaboration with RSM to establish a plan for DOH to assume all deployment activities to ensure complete ownership of these processes. This should assist with consistency in approach and execution going forward.	02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021. BHA initiated an RCA for the R3.12 defects to help with quality improvement and to ensure these same issues do not recur in future releases. Completion of the RCA is expected in early March. 01/31/2021 - A planned Mid-Sprint		Issue	High	Open	D Macdo	donald
19.000	12/31/2020	processes and technical execution issues, the project may continue to encounter defects and challenges in meeting projected timelines for production and non-production	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during	release and deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place.	execution of "Smoke Testing" for promotions to non-production and production environments. This will help to ensure that all components needed to test have been properly deployed prior to the actual execution of test activities. Work in collaboration with RSM to establish a plan for DOH to assume all deployment activities to ensure complete ownership of these processes. This should assist with consistency in approach and execution going forward. As appropriate, consult with RSM on best	02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021. BHA initiated an RCA for the R3.12 defects to help with quality improvement and to ensure these same issues do not recur in future releases. Completion of the RCA is expected in early March. 01/31/2021 - A planned Mid-Sprint Deployment (MSD) to production was released		Issue	High	Open	D Macdo	donald
19.000	12/31/2020	processes and technical execution issues, the project may continue to encounter defects and challenges in meeting projected timelines for production and non-production	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing	release and deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place.	execution of "Smoke Testing" for promotions to non-production and production environments. This will help to ensure that all components needed to test have been properly deployed prior to the actual execution of test activities. Work in collaboration with RSM to establish a plan for DOH to assume all deployment activities to ensure complete ownership of these processes. This should assist with consistency in approach and execution going forward. As appropriate, consult with RSM on best practices that BHA could employ to	02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021. BHA initiated an RCA for the R3.12 defects to help with quality improvement and to ensure these same issues do not recur in future releases. Completion of the RCA is expected in early March. 01/31/2021 - A planned Mid-Sprint Deployment (MSD) to production was released on 1/15/2021 to address high priority defects.		Issue	High	Open	D Macdo	donald
19.000	12/31/2020	processes and technical execution issues, the project may continue to encounter defects and challenges in meeting projected timelines for production and non-production	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically	release and deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place.	execution of "Smoke Testing" for promotions to non-production and production environments. This will help to ensure that all components needed to test have been properly deployed prior to the actual execution of test activities. Work in collaboration with RSM to establish a plan for DOH to assume all deployment activities to ensure complete ownership of these processes. This should assist with consistency in approach and execution going forward. As appropriate, consult with RSM on best practices that BHA could employ to support deployment.	02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021. BHA initiated an RCA for the R3.12 defects to help with quality improvement and to ensure these same issues do not recur in future releases. Completion of the RCA is expected in early March. 01/31/2021 - A planned Mid-Sprint Deployment (MSD) to production was released on 1/15/2021 to address high priority defects. Post MSD production issues resulted, and		Issue	High	Open	D Macdo	donald
19.000	12/31/2020	processes and technical execution issues, the project may continue to encounter defects and challenges in meeting projected timelines for production and non-production	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities	release and deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place.	execution of "Smoke Testing" for promotions to non-production and production environments. This will help to ensure that all components needed to test have been properly deployed prior to the actual execution of test activities. Work in collaboration with RSM to establish a plan for DOH to assume all deployment activities to ensure complete ownership of these processes. This should assist with consistency in approach and execution going forward. As appropriate, consult with RSM on best practices that BHA could employ to support deployment. Look at implementing 'hard' code freeze	02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021. BHA initiated an RCA for the R3.12 defects to help with quality improvement and to ensure these same issues do not recur in future releases. Completion of the RCA is expected in early March. 01/31/2021 - A planned Mid-Sprint Deployment (MSD) to production was released on 1/15/2021 to address high priority defects. Post MSD production issues resulted, and existing functionality was deprecated (e.g., SIS		Issue	High	Open	D Macdo	donald
19.000	12/31/2020	processes and technical execution issues, the project may continue to encounter defects and challenges in meeting projected timelines for production and non-production	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is	release and deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place.	execution of "Smoke Testing" for promotions to non-production and production environments. This will help to ensure that all components needed to test have been properly deployed prior to the actual execution of test activities. Work in collaboration with RSM to establish a plan for DOH to assume all deployment activities to ensure complete ownership of these processes. This should assist with consistency in approach and execution going forward. As appropriate, consult with RSM on best practices that BHA could employ to support deployment. Look at implementing 'hard' code freeze dates as well as test environment	02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021. BHA initiated an RCA for the R3.12 defects to help with quality improvement and to ensure these same issues do not recur in future releases. Completion of the RCA is expected in early March. 01/31/2021 - A planned Mid-Sprint Deployment (MSD) to production was released on 1/15/2021 to address high priority defects. Post MSD production issues resulted, and existing functionality was deprecated (e.g., SIS assessment scores). Although root cause		Issue	High	Open	D Macdo	donald
19.000	12/31/2020	processes and technical execution issues, the project may continue to encounter defects and challenges in meeting projected timelines for production and non-production	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to	release and deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place.	execution of "Smoke Testing" for promotions to non-production and production environments. This will help to ensure that all components needed to test have been properly deployed prior to the actual execution of test activities. Work in collaboration with RSM to establish a plan for DOH to assume all deployment activities to ensure complete ownership of these processes. This should assist with consistency in approach and execution going forward. As appropriate, consult with RSM on best practices that BHA could employ to support deployment. Look at implementing 'hard' code freeze dates as well as test environment deployment dates to ensure that testing	02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021. BHA initiated an RCA for the R3.12 defects to help with quality improvement and to ensure these same issues do not recur in future releases. Completion of the RCA is expected in early March. 01/31/2021 - A planned Mid-Sprint Deployment (MSD) to production was released on 1/15/2021 to address high priority defects. Post MSD production issues resulted, and existing functionality was deprecated (e.g., SIS assessment scores). Although root cause analysis is on-going, it is suspected these issues		Issue	High	Open	D Macdo	donald
19.000	12/31/2020	processes and technical execution issues, the project may continue to encounter defects and challenges in meeting projected timelines for production and non-production	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment	release and deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place.	execution of "Smoke Testing" for promotions to non-production and production environments. This will help to ensure that all components needed to test have been properly deployed prior to the actual execution of test activities. Work in collaboration with RSM to establish a plan for DOH to assume all deployment activities to ensure complete ownership of these processes. This should assist with consistency in approach and execution going forward. As appropriate, consult with RSM on best practices that BHA could employ to support deployment. Look at implementing 'hard' code freeze dates as well as test environment deployment dates to ensure that testing and deployment activities are not rushed.	02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021. BHA initiated an RCA for the R3.12 defects to help with quality improvement and to ensure these same issues do not recur in future releases. Completion of the RCA is expected in early March. 01/31/2021 - A planned Mid-Sprint Deployment (MSD) to production was released on 1/15/2021 to address high priority defects. Post MSD production issues resulted, and existing functionality was deprecated (e.g., SIS assessment scores). Although root cause analysis is on-going, it is suspected these issues stem from insufficient deployment and		Issue	High	Open	D Macdo	donald
19.000	12/31/2020	processes and technical execution issues, the project may continue to encounter defects and challenges in meeting projected timelines for production and non-production	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, or deployment notes, are	release and deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place.	execution of "Smoke Testing" for promotions to non-production and production environments. This will help to ensure that all components needed to test have been properly deployed prior to the actual execution of test activities. Work in collaboration with RSM to establish a plan for DOH to assume all deployment activities to ensure complete ownership of these processes. This should assist with consistency in approach and execution going forward. As appropriate, consult with RSM on best practices that BHA could employ to support deployment. Look at implementing 'hard' code freeze dates as well as test environment deployment dates to ensure that testing and deployment activities are not rushed. COMPLETED	02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021. BHA initiated an RCA for the R3.12 defects to help with quality improvement and to ensure these same issues do not recur in future releases. Completion of the RCA is expected in early March. 01/31/2021 - A planned Mid-Sprint Deployment (MSD) to production was released on 1/15/2021 to address high priority defects. Post MSD production issues resulted, and existing functionality was deprecated (e.g., SIS assessment scores). Although root cause analysis is on-going, it is suspected these issues stem from insufficient deployment and regression testing. DOH has confirmed that at		Issue	High	Open	D Macdo	donald
19.000	12/31/2020	processes and technical execution issues, the project may continue to encounter defects and challenges in meeting projected timelines for production and non-production	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, or deployment notes, are being utilized by BHA for	release and deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place.	execution of "Smoke Testing" for promotions to non-production and production environments. This will help to ensure that all components needed to test have been properly deployed prior to the actual execution of test activities. Work in collaboration with RSM to establish a plan for DOH to assume all deployment activities to ensure complete ownership of these processes. This should assist with consistency in approach and execution going forward. As appropriate, consult with RSM on best practices that BHA could employ to support deployment. Look at implementing 'hard' code freeze dates as well as test environment deployment dates to ensure that testing and deployment activities are not rushed. COMPLETED Request the assistance of the RSM Solution	02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021. BHA initiated an RCA for the R3.12 defects to help with quality improvement and to ensure these same issues do not recur in future releases. Completion of the RCA is expected in early March. 01/31/2021 - A planned Mid-Sprint Deployment (MSD) to production was released on 1/15/2021 to address high priority defects. Post MSD production issues resulted, and existing functionality was deprecated (e.g., SIS assessment scores). Although root cause analysis is on-going, it is suspected these issues stem from insufficient deployment and regression testing. DOH has confirmed that at least one needed software component was		Issue	High	Open	D Macdo	donald
19.000	12/31/2020	processes and technical execution issues, the project may continue to encounter defects and challenges in meeting projected timelines for production and non-production	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, or deployment notes, are	release and deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place.	execution of "Smoke Testing" for promotions to non-production and production environments. This will help to ensure that all components needed to test have been properly deployed prior to the actual execution of test activities. Work in collaboration with RSM to establish a plan for DOH to assume all deployment activities to ensure complete ownership of these processes. This should assist with consistency in approach and execution going forward. As appropriate, consult with RSM on best practices that BHA could employ to support deployment. Look at implementing 'hard' code freeze dates as well as test environment deployment dates to ensure that testing and deployment activities are not rushed. COMPLETED Request the assistance of the RSM Solution Architect in reviewing and correcting	02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021. BHA initiated an RCA for the R3.12 defects to help with quality improvement and to ensure these same issues do not recur in future releases. Completion of the RCA is expected in early March. 01/31/2021 - A planned Mid-Sprint Deployment (MSD) to production was released on 1/15/2021 to address high priority defects. Post MSD production issues resulted, and existing functionality was deprecated (e.g., SIS assessment scores). Although root cause analysis is on-going, it is suspected these issues stem from insufficient deployment and regression testing. DOH has confirmed that at least one needed software component was inadvertently missed from the deployment to		Issue	High	Open	D Macdo	donald
19.000	12/31/2020	processes and technical execution issues, the project may continue to encounter defects and challenges in meeting projected timelines for production and non-production	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, or deployment notes, are being utilized by BHA for	release and deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place.	execution of "Smoke Testing" for promotions to non-production and production environments. This will help to ensure that all components needed to test have been properly deployed prior to the actual execution of test activities. Work in collaboration with RSM to establish a plan for DOH to assume all deployment activities to ensure complete ownership of these processes. This should assist with consistency in approach and execution going forward. As appropriate, consult with RSM on best practices that BHA could employ to support deployment. Look at implementing 'hard' code freeze dates as well as test environment deployment dates to ensure that testing and deployment activities are not rushed. COMPLETED Request the assistance of the RSM Solution Architect in reviewing and correcting issues associated with consistency of the	02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021. BHA initiated an RCA for the R3.12 defects to help with quality improvement and to ensure these same issues do not recur in future releases. Completion of the RCA is expected in early March. 01/31/2021 - A planned Mid-Sprint Deployment (MSD) to production was released on 1/15/2021 to address high priority defects. Post MSD production issues resulted, and existing functionality was deprecated (e.g., SIS assessment scores). Although root cause analysis is on-going, it is suspected these issues stem from insufficient deployment and regression testing. DOH has confirmed that at least one needed software component was inadvertently missed from the deployment to production. The inconsistencies within the non-		Issue	High	Open	D Macdo	donald
19.000	12/31/2020	processes and technical execution issues, the project may continue to encounter defects and challenges in meeting projected timelines for production and non-production	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, or deployment notes, are being utilized by BHA for	release and deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place.	execution of "Smoke Testing" for promotions to non-production and production environments. This will help to ensure that all components needed to test have been properly deployed prior to the actual execution of test activities. Work in collaboration with RSM to establish a plan for DOH to assume all deployment activities to ensure complete ownership of these processes. This should assist with consistency in approach and execution going forward. As appropriate, consult with RSM on best practices that BHA could employ to support deployment. Look at implementing 'hard' code freeze dates as well as test environment deployment dates to ensure that testing and deployment activities are not rushed. COMPLETED Request the assistance of the RSM Solution Architect in reviewing and correcting issues associated with consistency of the configurations across environments,	02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021. BHA initiated an RCA for the R3.12 defects to help with quality improvement and to ensure these same issues do not recur in future releases. Completion of the RCA is expected in early March. 01/31/2021 - A planned Mid-Sprint Deployment (MSD) to production was released on 1/15/2021 to address high priority defects. Post MSD production issues resulted, and existing functionality was deprecated (e.g., SIS assessment scores). Although root cause analysis is on-going, it is suspected these issues stem from insufficient deployment and regression testing. DOH has confirmed that at least one needed software component was inadvertently missed from the deployment to production. The inconsistencies within the non-production and production environments		Issue	High	Open	D Macdo	donald
19.000	12/31/2020	processes and technical execution issues, the project may continue to encounter defects and challenges in meeting projected timelines for production and non-production	pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, or deployment notes, are being utilized by BHA for	release and deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place.	execution of "Smoke Testing" for promotions to non-production and production environments. This will help to ensure that all components needed to test have been properly deployed prior to the actual execution of test activities. Work in collaboration with RSM to establish a plan for DOH to assume all deployment activities to ensure complete ownership of these processes. This should assist with consistency in approach and execution going forward. As appropriate, consult with RSM on best practices that BHA could employ to support deployment. Look at implementing 'hard' code freeze dates as well as test environment deployment dates to ensure that testing and deployment activities are not rushed. COMPLETED Request the assistance of the RSM Solution Architect in reviewing and correcting issues associated with consistency of the	02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021. BHA initiated an RCA for the R3.12 defects to help with quality improvement and to ensure these same issues do not recur in future releases. Completion of the RCA is expected in early March. 01/31/2021 - A planned Mid-Sprint Deployment (MSD) to production was released on 1/15/2021 to address high priority defects. Post MSD production issues resulted, and existing functionality was deprecated (e.g., SIS assessment scores). Although root cause analysis is on-going, it is suspected these issues stem from insufficient deployment and regression testing. DOH has confirmed that at least one needed software component was inadvertently missed from the deployment to production. The inconsistencies within the non-		Issue	High	Open	D Macdo	donald

20.	000	3/28/2021	The pending RSM contract expiration	The RSM contract for Phase 3 is	DOH needs to be in a position		Project Management	Concern	Open	
			will require BHA to perform transition	currently planned to complete in	to completely stand on its own					1
			of the D365 solution to the State prior	September 2021. BHA will need to	without the assistance of					1
			to contract end.	ensure that it has all knowledge	vendor support by fall of 2021.					1
				transfer and is fully capable of	If DOH is not in a position to					1
				managing all aspects of supporting	solely take on the					1
				and maintaining the D365 solution	development of user stories,					
				without vendor support until at	testing, regression testing,					1
				least the Phase 4 expansion effort is	deployment, and the support					1
				procured and initiated. The Phase 4	and maintenance of the entire					1
				effort is currently expected to	system, there is a risk that					1
				commence late in the 4th quarter of	environment stability may be					1
				2021, or early in the first quarter of	challenged.					1
				2022. The Phase 4 procurement						1
				scope is planned to include						
				additional DD&I activities, as well as						1
				M&O support activities.						1